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 1 
1 Summary 
 
 
Hedgehog signaling plays a vital role in regulating varied fundamental processes 
including embryonic development, proliferation, and differentiation. Aberrant hedgehog 
signaling has been one of the reason for cancers such as Basal cell carcinoma (BCC), 
rhabdomyosarcoma (RMS) and medulloblastoma (MB). Medulloblastoma, a malignant 
pediatric brain tumor is one such cancer. Even after the development of impressive Hh 
pathway antagonists, drug resistance in medulloblastoma has been one of the most 
waffling issues which require identification of new drug targets. 
 
In the present study, increased histone deacetylase 6 (HDAC6) expression was observed 
in Hh-driven medulloblastoma and it is crucial for full Hh pathway activation. 
Interestingly, the stimulatory outcome/s of HDAC6 are partially integrated downstream 
of primary cilia, a known HDAC6-regulated structure. Further, HDAC6 is also essential 
for the repression of basal Hh target gene expression. These diverse outcomes are 
negotiated by HDAC6’s impact on Gli2 mRNA and GLI3 protein expression. As a 
consequence of this intricate interplay with Hh signaling, only a subset of Gli and 
Smoothened driven genes are regulated by HDAC6 apart from the well-known Hh targets 
such as Gli1 or Ptch1 which was shown by global transcriptome analysis. Overall, 
survival of medulloblastoma cells was critically compromised by in vitro inhibition of 
HDAC6 and blockade of HDAC6 pharmacologically greatly reduced tumor growth in an 
in vivo allograft model. 
 
In conclusion, the data illustrates the crucial aspects of HDAC6 in regulating the Hh 
pathway in mammals and encourage novel studies directed towards HDAC6 as a unique 
drug target in medulloblastoma. 
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1 Zusammenfassung 
 
 
Der Hedgehog Signalweg spielt eine wichtige Rolle bei der Regulation verschiedener 
fundamentaler Prozesse wie der Embryogenese, der Proliferation und der 
Differenzierung. Ein aberranter Hedgehog Signalweg trägt zur Krebsentstehung im der 
Lunge, dem Gehirn, der Brust, und der Haut. Das Medulloblastom, ein maligner 
Hirntumor der im Kindesalter auftritt, ist hierfür ein prominentes Beispiel. Die 
Resistenzentwicklung gegen etablierte Hedghog Signalweg-Antagonisten stellt ein ernst 
zu nehmendes Problem dar, welches die Aufklärung neuer pharmakologischer 
Angriffspunkte verlangt. 
 
In der vorliegenden Arbeit konnte eine erhöhte Histon Deacetylase 6 (HDAC6) 
Expression in durch Hedgehog Signalweg induziertem Medulloblastom gezeigt werden, 
welche ausschlaggebend für die vollständige Aktivierung des Signalweges ist. Die 
stimulatorischen Effekte von HDAC6 sind zum Teil downstream des Primärziliums zu 
finden, welches eine bekannte durch HDAC6 regulierte Struktur darstellt.Desweiteren ist 
HDAC6 essentiell für die Repression der basalen Hedgehog Signalweg Aktivität. Diese 
unterschiedlichen Effekte werden über die Regulation des mRNA Levels von Gli2 und 
die Protein Expression von GLI3 hervorgerufen. In einer Transkriptomanalyse konnte 
gezeigt werden, dass abgesehen von bekannten Hedgehog Zielgenen wie GLI1 oder 
PTCH1 lediglich eine Untergruppe von Gli und Smoothened Zielgenen durch HDAC6 
reguliert werden. Zudem beeinträchtigt eine in vitro Inhibition von HDAC6 das 
Überleben von Medulloblastoma Zellen entscheidend und die pharmakologische 
Blockade von HDAC6 reduziert das Tumorwachstum in einem allogenen in vivo Model. 
 
Zusammenfassend zeigen die Daten wichtige Aspekte von HDAC6 bei der Regulation 
des Hedgehog Signalweges in Säugern auf und legen den Grundstein für neue Studien 
über HDAC6 als interessanten Angriffspunkt zur Behandlung von Medulloblastoma. 
 
 
 
 3 
 
2 Introduction 
 
2.1 The Hedgehog signaling pathway 
 
 
Proper developmental control, metabolism and tissue homeostasis of multicellular 
organisms is a fine tuned and highly orchestrated process that depends on regulation of 
molecular signaling pathways in a spatial and context-dependent manner. The relevance 
of controlled activation and termination of signal is important to the functioning of all 
organisms. Despite molecular advances, our knowledge with respect to health and 
development of higher organisms and the pathways controlling them is sparse. One of the 
pathways which plays a very important role in development is Hedgehog (Hh)  signaling 
pathway (Teperino, Aberger, Esterbauer, Riobo, & Pospisilik, 2014). 
                                                                                                                                                                                                                                                                                        
The Hedgehog signal transduction pathway plays a quintessential role in mediating 
diverse fundamental mechanisms which comprise of cell proliferation, differentiation, 
survival, patterning, stem cell maintenance and tissue polarity (Gupta, Takebe, & 
Lorusso, 2010; Varjosalo & Taipale, 2008). The pioneering work of Eric F. Weischaus 
and Nusslein-Volhard in 1980 led to the discovery of the Hedgehog gene (Nusslein-
Volhard & Wieschaus, 1980). In their study, a mutational screen was performed that 
disrupted the body plan of Drosophila larvae. In general, the Drosophila larva is normally 
divided into various segments, the posterior part of each segment is smooth and the 
anterior part is coated in bristles which are known as denticles. In their mutational screen, 
they described a group of mutants that affected the segmental patterning. In these mutants 
known as polarity mutants, the posterior part of each segment did not develop properly 
or failed to develop resulting in a phenotype which was short and spiky similar to that of 
a hedgehog which led to the term hedgehog- gene (hh) (Ingham & McMahon, 2001; van 
den Brink, 2007; Varjosalo & Taipale, 2008).  
 
The mammalian Hh ligand family members consist of Desert Hedgehog (Dhh), Indian 
Hedgehog (Ihh) and the most common Sonic Hedgehog (Shh) (Chiang et al., 1996; 
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Echelard et al., 1993). In mouse and humans the three hedgehog genes are highly 
conserved (Marigo et al., 1995).  
 
The hedgehog proteins go through comprehensive and specific post-translational 
modifications and cleavage events producing a ~45 kDa precursor protein. This precursor 
protein is autocatalytically cleaved thereby giving rise to a cholesterol modified 19-kDa 
NH2-terminal fragment (HhNp) and an unmodified 26-kDa COOH terminal fragment 
(HhC) (J. a Porter, Young, & Beachy, 1996). The most striking feature of Hedgehog 
proteins is dual lipid modification of the19-kDa NH2- terminal fragment. The modified 
signalling protein is linked covalently to cholesterol and a palmitate group and is poorly 
soluble (Brink, 2007). The palmitoylation modification assist hedgehog protein/s to 
integrate in the cell membrane and play vital role in hedgehog signalling range in a tissue. 
The 26-kDa COOH terminal fragment acts as a cholesterol transferase and also catalyses 
the cleavage (Bumcrot, Takada, & McMahon, 1995; J. J. Lee et al., 1994; J. A. Porter et 
al., 1996; van den Brink, 2007). It was also recently demonstrated that palmitoylation 
promotes cleavage of amino acids at N-terminal by proteases like ADAM 
(metalloprotease and disintegrin family member) (Ohlig et al., 2011). This kind of 
cleavage leads to formation of active Shh multimers. These amino acids residues, if not 
cleaved, interrupt with the Zn2+ coordination sites on adjacent molecules and this region 
has been shown to interact with Ptch and is known to modulate Shh activity and stability 
(Bishop et al., 2009; Bosanac et al., 2009; Day et al., 1999; Fuse et al., 1999). 
 
The role of the cholesterol moiety is yet not clear (Lewis et al., 2001; Yina Li, Zhang, 
Litingtung, & Chiang, 2006; van den Brink, 2007).  The Hh proteins have an exclusive 
feature of travelling to long distances up to 300μm to reach their targets. Dispatched 
(Disp), a 12- pass transmembrane protein related to the bacterial RND (Resistance-
nodulation-cell division) family of transporters is essential for the release of long-range 
signalling of cholesterol and palmitate modified Hh (Burke et al., 1999; Caspary et al., 
2002; Kawakami et al., 2002; Ma et al., 2002). 
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2.2 The Mechanism of Hedgehog signal Transduction 
 
 
The transmission of Hedgehog signal takes place upon binding of Hedgehog ligands to 
12-span transmembrane receptors coded by genes PTCH1 and PTCH2 (Lisa V. Goodrich, 
Johnson, Milenkovic, McMahon, & Scott, 1996).  The receptors exhibit two extracellular 
loops which are hydrophilic in nature and negotiate Hedgehog binding (van den Brink, 
2007). The 12-pass transmembrane protein, Ptch  exhibits homology to bacterial transport 
proteins belonging to RND (Resistance-nodulation-cell division) family. The Ptch family 
of proteins consist of RND- derived domain and a sterol-sensing domain (SSD). The RND 
transport proteins are basically antiporters of proton and are involved in active efflux of 
various substrates across the cell membrane. These antiporters utilize the physiological 
proton levels at the cell membrane to pump out various substrates and in return allow the 
flow of other protons into the cell. The eukaryotic Ptch superfamily includes Dispatched 
(Disp) and Niemann-Pick C1 protein (NPC1). Dispatched is involved in release of Hh 
proteins whereas NPC1 is engaged in cholesterol homeostasis (Hausmann & Von Mering, 
2009). 
 
The Hh reception by Ptch is further enhanced by the presence of other Hh binding proteins 
at the cell surface. These additional coreceptors constitute fibronectin type III (FnIII) and 
immunoglobulin family of membrane proteins  Boi (Brother of Ihog) and Ihog 
(Interference hedgehog) in Drosophila and Boc (Brother of Cdo) and Cdo  (Cell adhesion 
molecule related/downregulated by oncogenes) in vertebrates and Gas1 which is a 
vertebrate specific surface protein (Allen et al., 2011; Beachy, Hymowitz, Lazarus, 
Leahy, & Siebold, 2010; Izzi et al., 2011).  
 
Apart from Boc, Cdo and Gas1 (Growth arrest specific protein1) vertebrates exhibit a 
fourth Hh-binding protein known as Hip.  Hip has no role in downstream signalling but 
competes with Ptch for Hh binding (Bosanac et al., 2009; Chuang & McMahon, 1999). 
Ptch plays a dual role in Hh signalling; on one hand, it is the receptor for Hh and on the 
other hand it serves as a negative regulator of Hh signal transduction pathway by 
inhibiting Smo, which is a seven-pass transmembrane protein.  
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When Hh ligands are absent Ptch localizes to primary cilium (PC) and represses signalling 
by inhibiting G-protein-coupled receptor (GPCR) (Eggenschwiler & Anderson, 2007) 
like signal transducer Smoothened (SMO) by entering into the primary cilium (Rohatgi, 
Milenkovic, & Scott, 2007). The way by which Smo is inhibited by Ptch still remains 
elusive.  It is assumed that repression of Smo by Ptc occurs via yet unidentified small 
molecule inhibitor (J. K. Chen, Taipale, Young, Maiti, & Beachy, 2002; Taipale, Cooper, 
Maiti, & Beachy, 2002).  
 
Recently, this assumption has been supported by small molecule inhibitors of Smo that 
mimic Ptc over-expression functionally (J. K. Chen et al., 2002; Frank-Kamenetsky et al., 
2002). These Smo antagonists seem to target the hepta-helical bundle belonging to Smo, 
the domain which is shown to be affected by Ptch (J. K. Chen et al., 2002) A major 
understanding into the regulation of Smo surfaced up when it was shown that oxidized 
cholesterol derivatives (oxysterols) specifically bind to the Cysteine-rich Domain (CRD) 
of Smo and are involved in activation of Hh pathway. Binding of Oxysterols by the CRD 
region of Smo can be functionally distinguished from binding of small molecules to the 
7TM (Trans membrane) site because deletion of Smo CRD leads to loss of Smo activation 
by oxysterols but do not alter the activity of agonists and antagonists targeting the 7TM 
region of Smo. It has been found in a screening that 7-keto-27-OHC and 7-keto-25-OHC 
both of which are 7-ketocholesterol metabolites activate Hh signaling in a CRD 
dependent way. The finding that Smo CRD can bind oxysterols and regulate Hh signaling 
throws some light on the route by which Smo may be modulated by Ptch (McCabe & 
Leahy, 2015). Recent work also suggests that Smo inhibition by Ptch may be non-
stoichiometric  (Taipale et al., 2002). It has been demonstrated in Drosophila that Ptch 
might inhibit Hh signalling by modulating the production of phosphatidylinositol 4-
phosphate (PI4P), acknowledging that decreasing and increasing levels of PI4P lead to 
Hh pathway repression and activation (Yavari et al., 2011). 
 
The principal mediators of canonical Hh signalling are the zinc finger containing Gli 
transcription factors. When Hh ligands are absent Gli-FL (Full length) is cleaved 
proteolytically by β-TRCP giving rise to N-terminal transcriptional repressor (Gli-R) 
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(Ramsbottom & Pownall, 2016). In Drosophila, there is only one Gli family member, 
Cubitus interruptus (Ci) whereas vertebrates exhibit three different Gli transcription 
factors Gli1, Gli2 and Gli3.  Among these Gli transcription factors Gli2 and Gli3 function 
both as repressors and activators. Gli1 functions mainly as an activator and it is also a 
target gene of Hh signalling (Fig. A1 and A2).  Albeit myriad facets of vertebrate Gli-R 
production remain elusive, Kif7 (Kinesin), Suppressor of Fused (Sufu) and the primary 
cilium are needed for adequate processing of Gli-FL into Gli-R (Cheung et al., 2009; 
Endoh-Yamagami et al., 2009; Goetz & Anderson, 2010; Liem, He, Ocbina, & Anderson, 
2009; Svärd et al., 2006).  
 
Sufu plays a very important role in stabilizing Gli2/Gli3 FL and retains both the proteins 
in cytoplasm, thereby preventing its nuclear translocation and activation (Humke, Dorn, 
Milenkovic, Scott, & Rohatgi, 2010; Tukachinsky, Lopez, & Salic, 2010; C. Wang, Pan, 
& Wang, 2010; Wilson & Chuang, 2010). Another vital role played by Sufu is the 
phosphorylation of  Gli-FL C-terminal residues by protein kinase A (PKA), which 
prepares Gli-FL for  next round of phosphorylation by Glycogen synthaseβ (GSK3β) and 
casein kinase1(CK1α) (Kise, Morinaka, Teglund, & Miki, 2009; Tempé, Casas, Karaz, 
Blanchet-Tournier, & Concordet, 2006). Recognition of phosphorylated Gli2/3-FL by E3 
ubiquitin ligase TrCP leads to ubiquitylation and finally the degradation of C-terminal 
peptides to form Gli-R (Bhatia et al., 2006; Kise et al., 2009; Tempé et al., 2006; B. Wang 
& Li, 2006).    
 
Protein Kinase A (PKA) is known to play key roles in many biological processes. In Hh 
receptive cells, PKA is involved in fate specification and in proliferation by attenuating 
Hh signaling. When the Hh pathway is inactive, even basal levels of active PKA can 
repress the Hh target genes. The important substrates of PKA are Gli transcription factors 
which are involved in repression and activation of Hh pathway. PKA is involved in 
phosphorylation of Gli thereby producing Gli repressors which then lead to repression of 
Hh target genes. When Hh ligands are present, the pathway is activated producing Gli 
activators eventually leading to Hh target gene expression. Due to fluctuations in the level 
of PKA activity, it is important to regulate PKA activity in Hh receptive cells precisely 
or it can lead to change in fate specification and aberrant proliferation of cells. It is not 
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very clear how PKA is regulated and still the mechanism remains elusive between various 
tissues, cell types and organisms. Two different mechanisms have been proposed to 
address the mechanism; (1) activity of PKA is regulated by cAMP; (2) PKA activity is 
regulated by protein known as Misty somites (Kotani, 2012).  PKA and CKI are involved 
in regulation of Smo accumulation at the cell surface in response to Hh. It has been shown 
in Drosophila wing disc, blockade of PKA and CKI leads to prevention of Smo 
accumulation upon Hh induction. Smo is phosphorylated by PKA and CKI at many sites 
and phosphorylation defective mutants of Smo are unable to accumulate at the cell surface 
and poorly equipped to transduce Hh signals. At the same time, it has also been shown 
that variants of Smo mimicking phosphorylation exhibit continuous expression at cell 
surface and also able to transduce signals (Jianhang Jia, Tong, Wang, Luo, & Jiang, 
2004). 
 
Another important player in the Hh pathway is the G-protein-coupled-receptor Gpr161. 
It plays an important role in Hh signaling by negatively regulating the pathway. The IFT-
A complex and Tulp3 are involved in trafficking of Gpr161 to the primary cilia (Pal & 
Mukhopadhyay, 2015). Expression of Gpr161 is mainly found in neural tube development 
and is localized in nervous system post mid-gestation period. It has also been found that 
Gpr161 is localized to cilia in many cultured cells and the ciliary localization is perturbed 
upon knockdown of Tulp3 and IFT-A complex in these fibroblasts (Mukhopadhyay & 
Rohatgi, 2014). Gli3 processing defects have also been observed in Gpr161 knockout 
mutants implying that Gpr161 could be pivotal in modulating this process. Mutational 
studies in Gpr161 double knock out mutants, have shown that Gli3 processing defects in 
these mutants are cilia dependent and takes place independent of Smo.  
 
 
The phenotypic appearance of Gpr161 is like that of Sufu and PKA mutants; anyhow 
Sufu effects on the Hh pathway takes place independent of primary cilia (M. H. Chen et 
al., 2009; Humke et al., 2010; Jinping Jia et al., 2009), indicating that Gli3 processing by 
Gpr161 is modulated via activation of PKA. When Shh is absent, Gpr161 is localized to 
primary cilium and is involved in promotion of increased levels of cAMP mediated 
through Gαs activation of adenylyl cyclase. Whereas, when the ligand is present Gpr161 
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moves away from the primary cilium thereby preventing production of cAMP and leading 
to pathway activation. Mainly, Gpr161 is involved in Shh signaling by stimulation of 
ligand,  regulating PKA, and roles in primary cilium (Pal et al., 2016).  
 
It is known that Hh signaling is involved in the division of brain cells also known as the 
granule neuron precursor cells (GNP). The regulation of these cells is tightly controlled 
but uncontrolled signaling leads to medulloblastoma. Neuropilins which are proteins bind 
to Semaphorin molecules and lead to activation of Hh signaling and eventually to 
medulloblastoma. Ge et. al (2015), demonstrated the role of Neuropilins in mice 
cerebellum and in cultured cells.  Their experimental data reveals that phosphodiesterase 
4D (PDE4D) which is an enzyme, accumulates at the cell membrane and is promoted by 
semaphorin3. The enzyme PDE4D upon interaction with neuropilin blocks the function 
of another enzyme which is normally involved in the inhibition of Hh signaling pathway.  
 
 
Mice that are deficient in semaphorin3 and neuropilin, the granule neuron precursor cells 
are unable to divide properly leading to development of abnormal cerebellum. They have 
also shown that drugs targeting PDE4D are capable of inhibiting tumor growths that are 
resistant to treatment with Vismodegib. The present PDE4D inhibitors suffer with severe 
side effects hence need of newer drugs. The findings of Ge et.al (2015), show a novel 
mechanism in which Hh signaling is regulated and highlights a novel strategy for 
medulloblastoma treatment (Ge et al., 2015).  
 
 
When Sufu is absent, Gli2-FL translocates to the nucleus and is converted into Gli2-A 
(upon phosphorylation by unknown kinase) which is labile and rapidly degraded by 
cullin-3-based ubiquitin ligase adaptor Spop (M. H. Chen et al., 2009; C. Wang et al., 
2010; Q. Zhang et al., 2006, 2009).  Apart from Sufu, Kif7 plays a cardinal role in Gli 
processing, though the exact mechanism is enigmatic but it is thought to recruit PKA, 
GSK3 and CK1 thereby phosphorylating Gli-FL (Ryan & Chiang, 2012).  
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Figure A: The key components of mammalian Hedgehog pathway. (1) When Hh ligands are absent, Patched (PTCH1, 12 -
transmembrane protein, shown in red)is present at the primary cilium’s base close to the centrosome (grey cylinders) and 
inhibits Smoothened (SMO, 7-transmembrane protein shown in green) from going into the cilium thereby shutting the 
pathway off. Activators Gli2/3A; Gli2 and Gli3 (yellow ovals) move up and down the cilium via intraflagellar transport 
plausibly with negative regulator supressor of fused (SUFU; shown in brown) and are cleaved by proteasome into repressor 
patterns (GLI2/3) which fail to activate transcription of target genes upon binding to DNA in nucleus.(2) In the presence of 
Hh ligands(purple spheres),PTCH1 moves out of primary cilium affecting its capability to inhibit SMO which later moves 
into the primary cilium thereby activating the pathway and preventing cleavage of GLI2 and GLI3. The binding of activated 
GLI2 and to a small tune GLI3 to GLI promoter sites leads to transcription of target genes, GLI1,PTCH1, HHIP and othe 
cell specific genes as CYCLINS and SNAIL. Degradation of Hh and PTCH1  takes place in lysosomes. (Image adapted and 
modified from-Scales & de Sauvage, 2009) 
 
 
2.3 Ptch1 a Tumor suppressor gene 
 
 
The Ptch1 gene codes for the PTCH1 protein and is the main receptor for the SHH 
signalling pathway. When the Hh ligands are absent, PTCH1 represses smoothened 
(SMO) and prevents it entry to primary cilium and further transcription of target genes 
which are important for normal development and growth thereby making it a negative 
regulator of the SHH pathway (Danwei Huangfu & Anderson, 2006). Gorlin-Goltz 
syndrome patients have high predisposition to medulloblastoma due to aberrant SHH-
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signalling pathway (Fujii & Miyashita, 2014). Gorlin-Goltz syndrome (GGS) is also 
known as nevoid basal cell carcinoma syndrome (NBCCS), basal cell nevus syndrome 
and multiple basalioma syndrome (Ramesh, Krishnan, Chalakkal, & Paul, 2015). It is 
highly penetrant and dominant autosomal disorder. It mainly occurs due to mutation in 
tumor suppressor gene, Ptch1. This gene is located at 9q22, 3-q31. The clinical features 
of this disease are normally detected between the first and third decades of life. This 
syndrome affects several organ systems including skin, eye, skeletal, neural as well as 
reproductive system  (Ramesh et al., 2015). The prevalence of this disease is around 1 in 
57,000 to 1 in 256,000 inhabitants. The ratio of the disease between male to female is 1:1. 
In the year 1960 Gorlin and Goltz, characterized the triad which encompasses 
odontogenic keratocysts (OKC), multiple basal cell carcinoma and bifid ribs when 
describing the syndrome. Early detection and diagnosis of GGS is pivotal because of the 
susceptibility of the patients to neoplasms (De Amezaga, Arregui, Nuño, Sagredo, & 
Urizar, 2008).  
 
 
2.4 Primary Cilium and Hedgehog Signalling  
 
 
The primary cilium is a solitary, non-motile, microtubule based structure that rise from 
cell surface of relatively all cell types in mammals including endothelial, epithelial, stem, 
muscle cells, neurons as well as connective tissues. (Satir, Pedersen, & Christensen, 2010) 
It was first termed as “primary cilia” by Sergei Sorokin (Sorokin, 1968). Primary cilia are 
normally produced during the G1 or quiescence phase of cell cycle (S. Kim & Dynlacht, 
2013). Growing information demonstrates that primary cilia are key modulators of varied 
signalling pathways like Hedgehog (Hh), Wingless (Wnt) and Platelet derived growth 
factor (PDGF) which are involved in development and tissue homeostasis (Berbari, 
O’Connor, Haycraft, & Yoder, 2009; Michaud & Yoder, 2006). Defective cilia and its 
components are the cause of many human developmental disorders and diseases which 
are known as Ciliopathies (Satir & Christensen, 2007). Ciliopathies encompass a 
collection of disorders that are linked to genetic mutations encoding abnormal proteins, 
leading to defective development or functioning of cilia. Some examples of ciliopathies 
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are Bardet-Biedl syndrome (BBS), Ellis van Creveld syndrome (EvC),  Polycystic kidney 
disease (PKD) and Meckel-Gruber syndrome (MKS) among various others (Waters & 
Beales, 2011). A number of ciliopathies are associated with Hh signaling. One such 
example is Nephronophthisis (NPHP) which is a cystic kidney disease and autosomal 
recessive in origin. Mutations in NPHP7/GLIS2 were observed in this disease which 
codes for the Kruppel-like zinc-finger transcription factor “Gli-similar protein 2”. It is 
localized to nucleus and the primary cilia. Knockout mouse model of Glis2 show fibrosis 
and renal atrophy, these mutant mice displayed upregulation of genes which were 
important in fibrosis and epithelial-to-mesenchymal transition (EMT). GLIS2 is closely 
associated to GLI family of transcriptional regulators and thereby connect NPHP to the 
Shh signaling pathway, which is known to play central role in tissue patterning and 
determination of cell fate (Hildebrandt, Attanasio, & Otto, 2009; Wolf & Hildebrandt, 
2011). 
 
 
The primary cilium principally consists of an axoneme that is made up of nine doublet 
microtubules that arise from the basal body and a septin like part at the base of the cilium 
which restricts access to the body. They are different from motile cilia in many ways. 
They are deficient in having the central microtubules and the radially distributed spokes 
that are needed for motility. The number of single microtubules and peripheral doublets 
are normally used to abbreviate microtubule ciliary axoneme configuration. Motile cilia 
have a 9+2 configuration, whereas non-motile cilia have a 9+0 configuration. The non-
motile primary cilia do not have the key elements needed for ciliary motility which 
include the central microtubules, proteins surrounding them, inner and outer dynein arms 
(Satir & Christensen, 2007).  The production of primary cilium is tightly regulated to the 
cell cycle. Trafficking occurs in a microtubule dependent way in the primary cilium and 
is monitored by multiprotein membrane bound complexes. The transport of proteins that 
takes place in both motile and primary cilia is known as intra flagellar transport (IFT). 
The IFT process is important for both maintenance and growth. IFT depends on the 
fundamental components of cilia like radial spokes, membrane proteins and tubulin. 
Various retrograde and anterograde molecular motors play vital role in trafficking of these 
multiprotein complexes from tip to basal body and vice versa (Robbins, Fei, & Riobo, 
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2012; Satir et al., 2010).  When Hh ligands are present, Ptch repression on Smo is relieved 
and allows Smo to be activated and enters the primary cilium. In Drosophila, PKA,CK1 
and G protein coupled receptor kinase2 (GRK2) phosphorylate the C-terminal residues 
which leads to conformational change in Smo and membrane accumulation (Apionishev, 
Katanayeva, Marks, Kalderon, & Tomlinson, 2005; Yongbin Chen et al., 2010; Jianhang 
Jia et al., 2004; Lum et al., 2003; Molnar, Holguin, Mayor, Ruiz-Gomez, & de Celis, 
2007; Su et al., 2011). The Smo C terminus in vertebrates is quite different from 
Drosophila and does not have phosphorylation sites for PKA but CK1 and GRK2 
phosphorylate the Smo C terminal residues which leads to conformational change and 
translocation to cilium (W. Chen, 2004; Yongbin Chen et al., 2011; Meloni et al., 2006). 
The Kinesin 2 motor subunit Kif3a and arrestins are required for Smo movement into the 
cilium upon its phosphorylation. Phosphorylation leads to Smo activation and inhibition 
of Gli processing. Apart from this, activated Smo leads to conversion of Gli-FL proteins 
into Gli-A and this is likely achieved by promoting the disassembly of Gli-Sufu 
complexes in the cilium (W. Chen, 2004; Yongbin Chen et al., 2011; Kovacs et al., 2008; 
Milenkovic, Scott, & Rohatgi, 2009). 
 
Recently, it has been demonstrated that the Rusc (RUN and SH3 domain) family of 
proteins play an important regulatory role in Hh signaling. In vertebrates, the family 
consists mainly of two proteins namely Rusc1 and Rusc2 (Jin et al., 2016). The Rusc1 
protein also known as Nesca is shown to be engaged in neurotrophin signal transduction 
pathway (MacDonald et al., 2012; Sun et al., 2012). Knockdown studies of Rusc1 in 
Xenopus embryos lead to increased Hh signaling amidst development of eye leading to 
acute ocular defects. Both the proteins (Rusc1/Rusc2) interact with Sufu leading to 
formation of a heterotrimeric complex with Gli and Sufu. When Hh signaling is activated 
this heterotrimeric protein complex is dissociated, Rusc2 exits first from the complex 
eventually leading to disassembly of Gli-Sufu complexes. Overexpression and 
knockdown studies of Rusc2 in the absence of Sufu has no overall output on Hh signaling 
indicative of its role in providing stability to the Gli-Sufu complexes. It seems that Hh 
signaling is inhibited by Rusc2, which binds to Sufu leading to stabilization of Gli-Sufu 
complexes thereby playing a regulatory role in the complex Hh signaling pathway (Jin et 
al., 2016). The disassembly of Gli-Sufu complexes leads to translocation of Gli-FL into 
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the nucleus and which is converted to Gli-A (Tukachinsky et al., 2010) leading to 
transcription of genes engaged in cell survival, proliferation and differentiation. The 
kinesin Kif7 is also thought to promote Gli-Sufu disassembly and plays a positive role in 
Hh signalling (Endoh-Yamagami et al., 2009). Apart from this, genes for negative 
regulators of Hh pathway like Ptch and Hip are also transcribed to regulate the pathway 
activity by negative feedback (Ryan & Chiang, 2012).  A number of enzymes have been 
shown to modulate Gli factors namely kinases and HDACs. Kinases like casein kinase I 
(CKI), glycogen synthase kinase 3 (GSK3) and Protein Kinase A (PKA) participate in 
regulating Hh pathway. All these three kinases interact with Cos2 and are involved in 
phosphorylation of homologous domains on Smo and Ci. Ci phosphorylation by CKI, 
GSK3 and PKA is needed for effective processing of Ci 155 to its repressor form namely 
Ci75 showing that these kinases have a blocking effect on Hh signaling (Y Chen, 
Gallaher, Goodman, & Smolik, 1998; Jianhang Jia et al., 2002; Price & Kalderon, 2002). 
Ci155 accumulates upon loss of phosphorylation by any of these kinases (Jianhang Jia et 
al., 2002; Price & Kalderon, 2002).  
 
The exact mechanism through which Hh negotiates the switch from negative effect to 
positive effects of these kinases is still elusive, but it has been suggested that it may be 
through reorganization of the Smo-Cos2-Fu-Ci complex upon reception of Hh (Aikin, 
Ayers, & Thérond, 2008). It has been shown that Dyrk1(Dual specificity tyrosine-
phosphorylation-regulated kinase), is a kinase involved in regulation of Gli1. Dyrk1 
modulates Gli1 activity by phosphorylating it at several serine/threonine sites and has 
been demonstrated to promote nuclear accumulation and Gli1-based transcription (Mao 
et al., 2002). Gli proteins transcriptional activity has been shown to be modified by many 
chromatin remodeling proteins and histone modifying enzymes. It has been demonstrated 
by Canettieri et al (2010) that acetylation alters Gli1/2 and HDACs class-I are involved 
in modulation of their transcriptional activity. In the granule cell precursors of 
cerebellum, Gli transcriptional activity is promoted by Hh signaling via HDAC1 
upregulation. The modulation of pathway occurs via REN-Cullin-3 ubiquitin ligase 
complex which leads to ubiquitination and proteasomal degradation of HDAC1. 
Interestingly, deacetylation due to overexpression of HDAC1/2 has not been shown to 
affect Gli3. Histone acetyltransferase (HATs) and cAMP response element binding 
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protein (CREB) are involved in transcriptional activation by Gli3 (P. Dai et al., 1999), 
whereas repressor action of Gli3’s is negotiated via Ski-based HDAC recruitment (P. Dai 
et al., 2002). The histone modifying enzymes namely HATs and HDACs alter Gli3 
directly or modify Gli3 function through chromatin remodeling has yet to be determined. 
 
 
2.5 Histone Deacetylases (HDACs) 
 
 
One of the most cardinal enzymes involved in epigenetic regulation of gene expression 
and chromatin remodelling are histone modifying enzymes. Chromatin remodelling 
between ‘closed’ and ‘open’ forms have important epigenetic role in regulation of gene 
expression. Nucleosome remodelling is required for such epigenetic changes to take 
place, the fundamental units of chromatin. i.e. histones have to be modified for such 
changes to take effect. A number of histone amino terminal tail modifications are 
involved which comprise phosphorylation, methylation, acetylation, ribosylation, 
sumoylation, ubiquitnylation, carbonylation and glycosylation.  
 
One of the important kind of modification is acetylation and is carried out by histone 
acetyltransferases (HATs) which transfer acetyl groups to lysine residues at amino-
terminal on histones. This results in chromatin expansion and greater accessibility for 
transcription factors to bind to DNA. On the other hand, histone deacetylases (HDACs) 
remove acetyl group from lysine residues leading to repression of transcription and 
condensation of chromatin (Nightingale, O’Neill, & Turner, 2006; Roth, Denu, & Allis, 
2001; Thiagalingam et al., 2003).  0 
 
It has also been reported that Histone deacetylases (HDACs) play important role in 
modifying the function of varied type of non-histone proteins, like signal transducing 
molecules and transcription factors (Drummond, Noble, Kirpotin, & Guo, 2005). For 
example, it has been shown that HDAC6 plays important role in repression of basal 
hedgehog target gene expression and the effects are negotiated by HDAC6’s impact on 
Gli2 mRNA and GLI3 protein expression (Dhanyamraju et al., 2015).    
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2.6 Classification of HDAC 
 
 
Histone deacetylases (HDACs) in mammals are mainly classified into four classes: class 
I, IIa, IIb and IV (Fig. B). The classification is based on molecular function and cellular 
localization (Federico & Bagella, 2011; Lane & Chabner, 2009). HDAC class I are 
universally expressed and nuclear in localization and includes HDACs 1,2,3 and 8. 
Knockout investigations have demonstrated that class I HDACs play important role in 
cell survival and proliferation (Haberland, Montgomery, & Olson, 2009; Marks, 2010). 
The class II HDACs include 4,5,6,7,9 and10, these HDACs can shuttle to and from 
nucleus to cytoplasm and vice versa and thought to be tissue restricted. Out of these class 
II HDACs, 6 and 10 (class IIb) are special due to the presence of two catalytic sites and 
play role in many different biological functions. Sirtuin family of structurally distinct and 
NAD+ dependent HDACs belong to class IIb and do not act directly on histones.  Finally, 
class IV includes HDAC11 which is universally expressed. Apart from histone targets, 
non-histone HDAC targets include NFκB, Ku70, p53, c-Myc, STAT3 and α-tubulin 
(Federico & Bagella, 2011). 
 
 
 
Figure B: Structural and functional domains of HDACs: The image depicts HDAC 1,2,3, and 8 from class I, HDAC 
4,5,7 and 9 from class IIa, HDAC 6 and 10 from class IIb and HDAC11 from class IV. HDACs with different structural 
and functional domains are also shown (Image adapted and modified from Bolden, Peart, & Johnstone, 2006). 
 17 
 
2.7 Histone deacetylase 6 - HDAC 6 
 
 
Histone deacetylase 6 (HDAC6) belongs to class IIb family of HDACs. It has a special 
place in class II family of HDACs due to presence of two homologous catalytic domains 
(Fig. C).  The overall functional activity of HDAC6 protein is maintained by the two 
independent catalytic domains (Grozinger, Hassig, & Schreiber, 1999; Verdel & 
Khochbin, 1999).  HDAC6 gene is located on Xp11.23 (http://www.ncbi.nlm.nih.gov/). 
It is the largest member of HDAC family and has around 1,216 amino acids (Grozinger 
et al., 1999; Yingxiu Li, Shin, & Kwon, 2013). Mainly, HDACs are localized to nucleus 
but class II HDACs are special due to their translocation to cytoplasm (de Ruijter, van 
Gennip, Caron, Kemp, & van Kuilenburg, 2003).  
 
 
HDAC6 is predominantly localized to the cytoplasm due to the presence of NES (Nuclear 
export signal) and SE14 motifs (C Boyault, Sadoul, Pabion, & Khochbin, 2007; de Ruijter 
et al., 2003). But, it has also been demonstrated that a small fraction of HDAC6 localizes 
to the nucleus (Verdel et al., 2000; Z. Wang et al., 2009). Nuclear localization of HDAC6 
is primarily due to the presence of nuclear localization signal (NLS) at the amino terminal 
end of HDAC6. The interaction of this region with importin helps HDAC6 to shuttle into 
the nucleus. Intriguingly, heavy acetylation of this region leads to blockage of importin 
and thereby leads to reduced HDAC6 amounts in the nucleus (Y. Liu, Peng, Seto, Huang, 
& Qiu, 2012). Detectable amounts of nuclear HDAC6 has also been observed in 
hematopoietic cells. HDAC6 is associated with nuclear factors and is involved in control 
of their activity (Gao, Cueto, Asselbergs, & Atadja, 2002; Girdwood et al., 2003; Palijan 
et al., 2009; Westendorf et al., 2002; Yang & Grégoire, 2005).  
 
 
Recruitment of HDAC6 to gene promoters and regulation of transcription has also been 
reported (Z. Wang et al., 2009). Acetylation plays a cardinal role in regulating the nuclear 
and cytoplasmic functions of HDAC6 (Y. Liu et al., 2012). HDAC 6 encompasses in its 
c-terminal an exclusive ubiquitin-binding zinc-ﬁnger domain (ZnF-UBP domain) and a 
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dynein binding domain (DBD) (G. M. Cooper & Hausman, 2000). HDAC6 functions as 
a cortactin, HSP90 and α tubulin deacetylase. It has also been shown that HDAC6 plays 
a significant role in multiple biological mechanisms which include role in immune 
synapse formation, cell spreading, cell migration, degradation of stress granules (SG), 
degradation of misfolded proteins and in viral infections via complex formation with 
various partner proteins (Yingxiu Li et al., 2013).  
 
The primary substrate of HDAC6 is α tubulin. Tubulin acetylation is carried out by a 
number of enzymes which include ELP3 (Creppe et al., 2009), GCN5, San15 (Conacci-
Sorrell, Ngouenet, & Eisenman, 2010), ARD-NAT1 and αTAT1(Akella et al., 2010; 
Shida, Cueva, Xu, Goodman, & Nachury, 2010; Topalidou et al., 2012) which are all 
acetyltransferases. Apart, from these HDAC6 and SirT2 are the deacetylases which are 
involved in deacetylation of microtubules (Hubbert et al., 2002; North, Marshall, Borra, 
Denu, & Verdin, 2003). 
 
 
One of the first well described α-tubulin acetylation was shown to be at ε-amino group of 
lysine40 in Chlamydomonas flagella (L’Hernault & Rosenbaum, 1983; LeDizet & 
Piperno, 1987). Tubulin acetylation is particularly enhanced in motile and primary cilia 
and therefore used as markers for the structures extensively (Piperno & Fuller, 1985). 
Assembly as well as disassembly of primary cilium has been shown to be impacted by 
acetylation of α-tubulin (Pugacheva, Jablonski, Hartman, Henske, & Golemis, 2007; 
Shida et al., 2010). α-tubulin acetylation has also been shown to be involved in 
acceleration of kinesin based transport along the axonal microtubule tracks (Reed et al., 
2006). Deletion of TAT2 and MEC17 which are the orthologues of αTAT1 in C.elegans, 
leads to reduction in sensitivity towards touch (Akella et al., 2010; Shida et al., 2010) and 
also leads to collapse of microtubule architecture in neurons for touch reception (Cueva, 
Hsin, Huang, & Goodman, 2012; Topalidou et al., 2012).  
 
 
Knockout of MEC17 which is an orthologue of αTAT1 in zebrafish leads to 
neuromuscular, developmental disorders (Akella et al., 2010). αTAT1 is one of the 
 19 
 
important and major player in acetylation of α-tubulin in mice and is necessary for typical 
flagellar function of sperm (Kalebic et al., 2013). It has been shown that it plays 
significant role in oncogenic cell transformation, hence has become a prime target for 
drug development to treat cancers. Previous work has demonstrated that, inhibition of 
HDAC6 leads to apoptosis in multiple myeloma cells. In some cancers, HDAC6 is also 
used as prognostic marker. HDAC6 and HSF1 regulate oncogenic Ras/MAPK signal 
transduction pathway required for proper tumour growth (C. Dai, Whitesell, Rogers, & 
Lindquist, 2007; Y. S. Lee et al., 2008a). Its interaction with cortactin regulates motility. 
HDAC6 contributes to cancer metastasis since its upregulation increases cell motility in 
breast cancer MCF-7 cells and its interaction with cortactin modulates motility (Sakamoto 
& Aldana-Masangkay, 2011).  
 
It is engaged in microtubule control and actin dependent cell motility. HSP90, a 
chaperone protein is also a HDAC6 substrate. Among other important functions; HDAC6 
plays a critical role in misfolded protein clearance by autophagy or via generation of 
aggresomes (Delcuve et al., 2012). Keeping all these functions in view HDAC6 is 
candidate therapeutic target for treatment of diseases like cancer and neurodegenerative 
diseases (G. Li, Jiang, Chang, Xie, & Hu, 2011; Sakamoto & Aldana-Masangkay, 2011; 
Valenzuela-Fernández, Cabrero, Serrador, & Sánchez-Madrid, 2008). 
 
 
 
 
 
 
 
 
 
 
 
Figure C: Image depicts functional domains of HDAC6. It has two tandem catalytic deacetylase domains (DD1 and 
DD2). Hsp90, Cortactin andα tubulin are substrates for HDAC6. Nuclear export signal (NES) restricts the accumulation 
of protein in nucleus. The Ser-Glu tetrapeptide (SE14) part provides a strong platform for the enzyme in the cytoplasm. 
The binding of dynein and ubiquitin-binding zinc ﬁnger domain (ZnF-UBP) is accomplished by linker between both 
DDs. Zn+ (Zinc) cofactor at active site. Dynein motor binding domain (DMB). Nuclear localization signal (NLS) (Image 
adapted and modified from (S. N. Batchu et al., 2016). 
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2.8 Regulation of ciliogenesis by HDAC6 
 
 
The primary cilium is a microtubule based small antenna like structure and has been 
shown to play cardinal roles in varied cellular functions like cell growth, cell migration, 
cell cycle, planar cell polarity, immune response and transactivation. Keeping in view 
such important and diverse functions of the cilium, any dysfunction in ciliary function 
leads to diseases known as the ciliopathies (Suizu et al., 2016). In Bardet-Biedl Syndrome 
(BBS), polycystic kidney disease (PKD) and other cilia related diseases mutations in 
signaling proteins or cilia related proteins lead to insensitivity to foreign signaling cues 
leading to hyperplastic growth (Benzing & Walz, 2006; J Pan, Wang, & Snell, 2005; 
Singla & Reiter, 2006). It has recently been shown that several signaling pathways like 
Wnt, PDGFαα, hedgehog and other signaling pathways coordinate at cilia (Cano, Murcia, 
Pazour, & Hebrok, 2004; A. Liu, 2005; Schneider et al., 2005; Simons et al., 2005; 
Tanaka, Okada, & Hirokawa, 2005).  
 
Even though a large number of ciliary proteins involved in structural and functional roles 
of cilia have been identified, the current knowledge about cellular machinery regulating 
cilia resorption and formation is sparse. Regulation of cilia throughout the cell cycle is a 
very dynamic process. In varied cells, ciliary resorption takes place at mitotic entry and 
ciliary reappearance post entry to G1. Taking into consideration the important role/s 
played by cilia in detection and transmitting external cues, cilia shortening and 
disassembly might play a cardinal role in growth control and aberrant cell growth signals 
in the external environment (Pugacheva, et al., 2007).  
 
The primary cilium principally consist of an axoneme that is made up of nine doublet 
microtubules that arise from the basal body and a septin like part at the base of the cilium 
which restricts access to the body (Satir & Christensen, 2007).  Motile flagella of lower 
eukaryotes like Chlamydomonas are related evolutionarily to the cilium. Recently, 
research focusing on Chalmydomonas have started to understand the mechanism of 
resorption of flagella (Bradley, 2005; Marshall, Qin, Rodrigo Brenni, & Rosenbaum, 
2005; Junmin Pan & Snell, 2005; Quarmby, 2004). These investigations found altered 
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capabilities of the IFT machinery and axonemal destabilization as indicative marks of 
ciliary disassembly, and suggested the role of CALK (Chlamydomonas aurora-like 
protein kinase) and other kinases as main regulators of ciliary disassembly. The exact 
mechanism of how CALK and other effectors are activated in disassembly still remains 
elusive. CALK kinase shares a 55% similarity to that of human Aurora A (AurA) kinase 
around the protein catalytic domain. Aurora A plays a very important role in humans as 
a centrosomal kinase regulating mitotic entry via activating Cdk1-cyclin B and other 
important molecules that are involved in organization of mitotic spindle (Bischoff et al., 
1998; Marumoto, Zhang, & Saya, 2005). In varied cancers, it has been observed that 
AurA is activated or amplified which can be characterized by amplification of centrosome 
and genomic instability (Anand, Penrhyn-Lowe, & Venkitaraman, 2003; Goepfert et al., 
2002; Gritsko et al., 2003). 
 
HEF1 (human enhancer of filamentation 1) is a scaffolding protein and is known to play 
important roles in migration, attachment & anti-apoptotic cues at focal adhesions (O'Neill 
et al., 2000). It has been recently demonstrated that AurA and HEF1 interact with each 
other at the centrosome which is needed for cell progression over mitosis (Pugacheva & 
Golemis, 2005, 2006). Looking for targets phosphorylated by AurA, Pugacheva et al., 
(2007) considered acetylated α-tubulin because it has been shown that α-tubulin 
deacetylation led to microtubule destability in vivo (Matsuyama et al., 2002). It has been 
demonstrated that Histone deacetylase 6 (HDAC6) plays important role as tubulin 
deacetylase and effects chemotaxis and mitosis via controlling tubulin stability (Hubbert 
et al., 2002). Pugacheva et al., (2007) showed that HDAC6 plays an important role in 
ciliary disassembly mediated by Aurora A. When HDAC6 is depleted in cells, Aurora A 
activation does not lead to disassembly of cilium pointing that HDAC6 operates 
downstream of Aurora A. It has also been shown that HDAC6 is phosphorylated by 
Aurora A in vitro (Pugacheva et al.,2007). The model proposed by Pugacheva et al., 
(2007) show that external growth factors promote disassembly of cilia via activation of 
HEF1 expression, which then activates Aurora A. Aurora A eventually phosphorylates 
HDAC6. Upon phosphorylation HDAC6 destabilizes primary cilium microtubules via 
deacetylation of axonemal tubulin thereby causing ciliary resorption (Pugacheva et al., 
2007) (Fig.D). 
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2.9 Hedgehog signaling and Cancer 
 
 
The molecular processes/mechanisms leading to aberrant activation of Hh pathway has 
been one of the main reasons for Hh associated cancers. Three basic models of pathway 
activation have been proposed (Rubin & de Sauvage, 2006; Scales & de Sauvage, 2009). 
Type I cancers are those containing activating mutations in Hh pathway which are 
independent of ligand like Medulloblastoma (MB) and Basal cell carcinoma (BCC). Type 
II cancers are ligand dependent (autocrine or juxtacrine) mechanisms; which means that 
Hh is produced and also utilized by same cells or neighboring tumor cells. Type III are 
ligand dependent paracrine signaling mechanisms in which Hh produced by the cancer 
cells are collected by stroma which further feed the cells with other signals leading to 
survival and growth of tumors. (Rubin & de Sauvage, 2006; Scales & de Sauvage, 2009).   
 
2.10 Hedgehog signaling Type I: mutation driven, ligand independent 
 
The very first indication of Hh pathway involvement in cancers was acknowledged when 
Ptch inactivating mutations were described in a condition known as Gorlin’s syndrome 
Figure D: Regulation of ciliogenesis by HDAC6: (A) To the basal body of quiescent ciliated cells Aurora A (AurA) and 
low amounts of HEF1 are localized. (B) Induction of HEF1 by growth factors leads to activation of Aurora A which 
eventually results in phosphorylation of ciliary HDAC6 (H6), thereby resulting in resorption of cilia. Image adapted and 
modified from Pugacheva et al., 2007 
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(Hahn et al., 1996; Johnson et al., 1996). Patients suffering with Gorlin’s syndrome show 
up with many BCCs and are at higher risk of developing rhabdomyosarcoma (Muscle 
tumor) and medulloblastoma (brain tumor). It has also been demonstrated that ligand 
independent activation of hedgehog pathway (Fig.E1) was seen in most random cases of 
BCCs (Dahmane, Lee, Robins, Heller, & Ruiz i Altaba, 1997).  
 
In majority of tumors SMO activating mutations (10%) and PTCH inactivating mutations 
were observed (Xie et al., 1998). Moreover, in 1/3rd of medulloblastoma cases and in 
rhabdomyosarcomas Ptch and Sufu mutations have led to Hh pathway activation 
aberrantly (Taylor et al., 2002; Tostar et al., 2006). Increased tumor formation and high 
cell proliferation have been shown as a result of aberrant Hh signaling. In many different 
mice models the same observations have been noticed and confirmed. As in Gorlin’s 
syndrome patients, mice carrying heterozygous Ptch mutations are predisposed to 
medulloblastomas and are sensitive to BCC upon exposure to UV (Ultraviolet) 
(Aszterbaum, Beech, & Epstein  Jr., 1999).  Many patients with metastatic BCC are being 
treated with Hh pathway inhibitors, because these tumors are not dependent on ligand the 
inhibitors should be targeted at or below the level of Smo in the Hh pathway to be 
productive (Gupta et al., 2010). 
 
 
2.11 Hedgehog signaling Type II: Autocrine, ligand dependent 
 
 
In several tumors like prostrate, liver, breast and brain constant Hh pathway activation 
has been detected (Gupta et al., 2010) These tumors differ from medulloblastomas and 
BCC in that they do not display any somatic mutations in the hedgehog pathway. They 
show aberrant Hh pathway activation in a ligand dependent and autocrine manner (Fig. 
E2). Several of these tumors exhibit high expression levels of Shh or Ihh and /or ectopic 
Gli1 and Ptch expression in the epithelial section. Ligand production ectopically by tumor 
cells or tumor stem cells (TSC) works on surrounding tumor cells or itself leading to its 
own survival and growth. This autocrine mode of signaling in these tumors can be 
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inhibited by using Smo antagonists and/or antibodies against Hh pathway (Gupta et al., 
2010). 
 
2.12 Hedgehog signaling Type III: Paracrine, ligand dependent 
 
 
The paracrine mechanism of Hh signaling (Fig.E3)  is pivotal for development and in 
maintaining epithelial structures like the small intestine (Ingham & McMahon, 2001; 
Theunissen & de Sauvage, 2009; Varjosalo & Taipale, 2008). Epithelium secreted Hh 
ligands are detected by the mesenchymal stroma cells and lead to stimulation and 
eventually proliferation in the mesenchyme. When Hh pathway is activated, the 
mesenchymal cells generate molecules which ultimately feed back to the epithelial cells. 
Recently it was reported by Yauch et al (2008) that paracrine way of Hh signaling play 
an important role in improving the tumor microenvironment (Jiang & Hui, 2008; Yauch 
et al., 2008).  
 
It was demonstrated by Stevaux et.al (2009) that deletion of Smo by genetic means do 
not lead to change in Gli1 and Ptch expression in neoplastic ductal cells and do not lead 
to progression of pancreatic adenocarcinoma (Nolan-Stevaux et al., 2009). All these 
reports suggest and support the paracrine mode of Hh signaling, in which Hh signaling is 
activated in surrounding stroma leading to the production of extracellular matrix 
molecules and soluble components which act on tumor epithelium eventually leading to 
tumor growth (Theunissen & de Sauvage, 2009). The most efficient way of treating these 
tumors would be by using a combination therapy; an inhibitor targeting the Hh pathway 
in stromal cells and other drugs directed towards the tumor cells (Gupta et al., 2010). 
 
 
2.13 Hedgehog signaling Type III b: Reverse Paracrine signaling  
 
 
Lately, a “reverse paracrine” mode of signaling (Fig.E4)  has also been demonstrated in 
which stromal cells secrete the Hh and is detected by the tumor cells (Theunissen & de 
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Sauvage, 2009). Till now this mode of signaling has only been observed in hematological 
malignancies like leukemia, lymphoma and multiple myeloma in which stromal secreted 
Hh is utilized by cancerous B cells through upregulation of Bcl2, which is an antiapoptotic 
factor (Dierks et al., 2007; Hegde et al., 2008; Scales & de Sauvage, 2009). In this model, 
the Hh secreted by the stromal cells is thought to support the environment needed for 
effective tumor growth and thereby can be used as suitable drug target (Gupta et al., 
2010). 
 
 
2.14 Hedgehog signaling in cancer stem cells 
 
 
Stem cells are involved in tissue maintenance and have the capacity to form and give rise 
to new stem cells and are able to differentiate into mature cells of a tissue. Hh signaling 
plays a pivotal role in activity of stem cells, self-renewal and multiplication of these cells 
in many tissues (Taipale & Beachy, 2001; Y Zhang & Kalderon, 2001). It is considered 
that small CSCs populations help tumors to propagate and grow (Fig.E5). These small 
CSCs have similar properties like that of normal stem cells and are normally regulated by 
similar kind of signaling factors like that of normal stem cells (Reya, Morrison, Clarke, 
& Weissman, 2001). 
 
Increasing data conveys that tumor formation and expansion are directly a result of 
aberrant signaling pathways in stem cells like Wnt, notch, and the Hh pathways (Rubin 
& de Sauvage, 2006). It has been demonstrated that Hh signaling plays important role in 
self-renewal and maintenance of CSCs in multiple myeloma, breast and chronic 
myelogenous leukemia (CML) stem cells (Clement, Sanchez, de Tribolet, Radovanovic, 
& Ruiz i Altaba, 2007; Dierks et al., 2008; S. Liu et al., 2006; Peacock et al., 2007; 
Theunissen & de Sauvage, 2009). Dierks et al (2008) demonstrated that CML stem cells 
(Bcr-Abl driven Lin-/Sca1+/c-Kit+) having a SMO knockout exhibited decreased capacity 
to form tumors in mice which were irradiated despite the fact that SMOM2 expression 
led to enhancement (Dierks et al., 2008; Peacock et al., 2007).  Moreover, when 5E1 (Hh 
blocking antibody) and cyclopamine (SMO antagonist) was used both of them led to the 
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inhibition of CML CSCs in vivo and in vitro. The loss of Smoothened in hematopoietic 
system of mouse led to diminished induction of chronic myelogenous leukemia by the 
oncoprotein Bcr-Abl and activated Numb, leading to reduction of CML stem cells. 
Growth inhibition was observed in imatinib-resistant human and mouse CML by 
cyclopamine, pointing that Hh signaling can be targeted in the treatment of imatinib-
resistant CML (Zhao et al., 2009). The increasing evidence that active Hh signaling plays 
important role in varied type of CSCs makes it a hopeful target by inhibiting the Hh 
pathway in these tumors forming CSCs. This can be achieved by using a combination of 
drug therapies: one targeting the Hh signaling in CSCs and the other for the bulk of the 
tumor or in combination with radiation (Scales & de Sauvage, 2009). It was shown by 
Feldmann et al., (2007) in pancreatic cancer cells that GLI expression ectopically leads 
to greater invasiveness, whereas Hh pathway inhibition leads to Snail downregulation 
thereby decrease in invasive characteristics (Feldmann et al., 2007). Tumor metastasis 
has also been shown to be promoted by Hh signaling by playing an active role in epithelial 
to mesenchymal transition (EMT).  EMT consists of converting epithelial cells which are 
polarized into mesenchymal cells which have invasive and migratory characteristics 
eventually leading to metastasis. Hh exercises its effects on EMT through down 
regulation of E-cadherin and upregulation of SNAIL (Karhadkar et al., 2004; Rubin & de 
Sauvage, 2006). 
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Figure E: Diverse models of Hedgehog signaling pathway: (1) Type I ligand independent cancers contain activating 
mutations in Smoothened (SMO) or inactivating mutations in Ptch1 (PTCH) which lead to continuous activation of the 
Hh pathway even when the ligand is not present. (2) Type II are autocrine cancers which are ligand dependent. These 
cancers produce and use the Hh ligands which eventually leads to tumor survival and growth. (3) Type III are paracrine 
cancers which are ligand dependent. These cancers produce ligands which are detected and received by stromal cells 
which lead to activation of pathway in the stroma. The stromal cells in turn feeds back variety of signals like IGF 
(Insulin-like growth factor), VEGF (Vascular endothelial growth factor), Wnt (Wingless) to the tumors thereby leading 
to survival and growth. (4) Type IIIb are cancers which exhibit reverse paracrine signaling. Tumors detect and receive 
Hh ligand secreted by stromal cells thereby leading to activation of pathway in tumor cells via upregulating survival 
cues. (5) Cancer stem cells (CSCs): Hh ligands produced by stroma or CSCs lead to Hh signaling only in self-renewing 
CSCs. These CSCs will propagate further and give more CSCs which are Hh pathway dependent or may differentiate 
into tumor cells which are Hh negative consisting majority of the bulk cells of the tumor. Image adapted and modified 
from: Scales, S.J. and de Sauvage, F.J. (2009). 
 
 
2.15 Hedgehog signaling in Central Nervous System (CNS) Tumors 
 
 
Even though much information regarding Hh signaling in medulloblastoma is known, the 
role of Hh signaling and its role in other CNS tumors is sparse. Very few cases have been 
reported showing Smo or Ptch1 mutations in extra cerebellar tumors. In 1987, for the very 
first time it was shown that Hh signaling plays role in Gliomagenesis, when Gli1 gene 
was isolated from Glioblastoma cell line (Kinzler et al., 1987). Analysis of several 
primary tumors like glioblastoma, astrocytoma, oligodendroglioma, PNETs (Primitive 
neuroectodermal tumor) and other cell lines show constitutive Gli1 expression (Dahmane 
et al., 2001). It was shown that growth inhibition of several human glioma cell lines was 
noticed when Cyclopamine (hedgehog pathway inhibitor) was used indicating that these 
tumors rely upon Hh signaling pathway for their survival and growth (Dahmane et al., 
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2001).  Recent studies have pointed a role of neural stem cells in brain tumors, the idea 
emerges from the fact that many primary tumors like oligodendrogliomas and 
astrocytomas express neural stem cell markers and are capable of undergoing self-
renewal as well as undergo differentiation in vitro (Hemmati et al., 2003; Oliver & 
Wechsler-Reya, 2004; Singh, Clarke, Hide, & Dirks, 2004). As Hh signaling has been 
demonstrated to be important for neural progenitor cell maintenance in the hippocampus, 
it is very reasonable to hypothesize that this pathway might also play a role in 
tumorigenesis outside the cerebellum (Lai, Kaspar, Gage, & Schaffer, 2003; Machold et 
al., 2003). Anyhow, further research is needed to know if mutations in certain players of 
the pathway are necessary for tumor initiation or they are just needed for tumor survival 
and growth. Finally, tumors of the CNS can be targeted by using pharmacological 
inhibitors (Marie P. Fogarty, Kessler, & Wechsler-Reya, 2005). 
 
 
2.16 Medulloblastoma (MB) 
 
 
Medulloblastoma (MB) is one of the most common, highly invasive paediatric brain 
tumour arising from embryonal cells of the cerebellum. It accounts for around 20% of all 
paediatric brain tumours (de Bont, Packer, Michiels, den Boer, & Pieters, 2008; Pui, 
Gajjar, Kane, Qaddoumi, & Pappo, 2011). MB was described initially as cerebellar 
glioma before Bailey and Cushing named it as medulloblastoma in 1925 (Bailey & 
Cushing, 1925).  
 
Patients with MB present clinical and slight neurological symptoms that prevail for few 
months before diagnosis. The symptoms include lethargy, vomiting, headaches, ataxia, 
cranial nerve defects, facial weakness, hearing loss, ringing in the ears, Parinaud’s 
Syndrome (pupillary defect and upward gaze) and head tilt etc. (Huang & Yang, 2015). 
MB has been described by pathologists as a heterogenous disease and according to the 
World Health Organisation (WHO) it has been classified into (1) Classic 
medulloblastoma and four subtypes based on histological constitution: (2) Nodular or 
desmoplastic (D/N); (3) Medulloblastoma with extensive nodularity (MBEN); (4) 
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anaplastic medulloblastoma and (5) large-cell variant (A. J. Gajjar & Robinson, 2014; 
Louis et al., 2014), the histopathologic features of each class are given below: 
 
 
2.16.1 (1) Classic Medulloblastoma (CMB) 
 
 
It is one of the most common and frequent kind of medulloblastoma and accounts for 70-
80% of all known cases (Gilbertson & Ellison, 2008; Pizer & Clifford, 2009). It is 
characterized by circular hyperchromatic nuclei, moderate nuclear pleomorphism (D.W. 
Ellison, 2002; D. W. Ellison, 2010) and have small tiny sheets of cells exhibiting high 
nuclear: cytoplasmic ratio when stained with H&E (Hematoxylin and Eosin) (D.W. 
Ellison, 2002) (Fig.F1). The presence of apoptotic bodies can also be seen in tumor cells 
along with mitotic figures (D.W.Ellison, 2002; D. W. Ellison, 2010).  
 
 
2.16.2 (2) Desmoplastic or Nodular (D/N) medulloblastoma 
 
 
The nodular desmoplastic medulloblastoma (DNMB) accounts for 10-15% of the 
medulloblastoma cases. It is identified by internodular desmoplasia and the nodules 
consist of differentiated neurocytic cells (Fig.F2). These differentiated cells express 
neuronal proteins and exhibit poor growth fraction. The internodular desmoplastic zones 
are represented by embryonal cells which are undifferentiated and in between the nodules, 
collagen positive strands can be observed which are reticulin positive (D. W. Ellison, 
2010). In this subtype, the degree of nodularity is quite unstable and it has been shown 
that increased nodularity is linked to better prognosis (McManamy et al., 2007). 
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2.16.3 (3) Medulloblastoma with extensive nodularity (MBEN)  
 
 
The histological features of this class are similar to that of the desmoplastic variant. This 
subtype makes around 1% of medulloblastomas (McManamy et al., 2007).  In comparison 
to desmoplastic tumors, MBENs consists of irregularly shaped large nodules. One of the 
essential features of this subtype is decreased desmoplastic elements between the nodules 
(D. W. Ellison, 2010) (Fig.F3). 
 
 
2.16.4 (4) Large cell medulloblastoma  
 
 
This medulloblastoma subtype accounts for around 2-4% of the disease (D. Ellison, 2002; 
McManamy et al., 2007). It consists of groups of cells which are large and round having 
single nucleolus (Fig.F4). These cells exhibit high mitotic rate and also higher apoptotic 
rate when compared to other subtypes (McManamy et al., 2003). This subtype has poor 
prognosis and usually shows up as a metastatic disease (A. Gajjar et al., 2004). 
 
 
2.16.5 (5) Anaplastic medulloblastoma  
 
 
Anaplastic medulloblastomas makeup for 10-20% of the disease (Gilbertson & Ellison, 
2008). The histopathologic characters of this class include wrapping of cells, paved 
arrangement of nuclei, cell moulding and nuclear pleomorphism (Brown et al., 2000; 
Eberhart et al., 2002) (Fig.F5). High apoptotic and mitotic activity can be seen in this 
class (McManamy et al., 2003). Anaplastic medulloblastomas like that of large cell 
variant show poor prognosis (Eberhart et al., 2002; McManamy et al., 2003). Due to 
similar histologic aspects and biological behavior between anaplastic and large cell 
variant, they are commonly grouped into single large cell/anaplastic (LCA) class in 
medulloblastoma research (Gilbertson & Ellison, 2008). 
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Due to rapid development of novel genomic tools the molecular classification of MB has 
been possible which is based on genetic alterations and distinct transcriptional profiles. 
Based on this approach, MB has been categorized into four molecular subtypes: wingless 
pathway MB (Wnt-MB; subtype 1), sonic hedgehog MB (SHH-MB; subtype 2), MYC-
Figure F: Histopathological classification of medulloblastoma: (1) classic, (2) desmoplastic/nodular (D/N), (3) 
medulloblastoma with extensive nodularity (MBEN), (4) large-cell medulloblastoma, and (5) anaplastic 
medulloblastoma. Images adapted and modified from (Eberhart, 2011; D. W. Ellison, 2010). 
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ampliﬁed MB (subtype 3), and heterogeneous (subtype 4) (Cho et al., 2011; Kool et al., 
2012; K. K. W. Li, Lau, & Ng, 2013; Northcott, Jones, et al., 2012; Pietsch et al., 2014; 
Sadighi, Vats, & Khatua, 2012; Thompson et al., 2006) (Fig. G). The Subtype1 (Wnt -
MB) is seen in comparable amounts both in children and adults and has a better prognosis. 
This subtype is characterized by Wnt signalling, MYC expression and monosomy 6 and 
accounts for around 10% of all medulloblastomas (Northcott, Dubuc, Pfister, & Taylor, 
2012). Subtype 2 (SHH-MB) normally affects children below 5 years and adolescents 
above 16 years. Activating mutations in smoothened (SMO), inactivating mutations in 
patched1 (PTCH1) and SUFU  are commonly seen in this subtype, apart from MYC and 
GLi2 amplification (Hallahan et al., 2004a) and the frequency of this subtype is around 
30% (Northcott, Dubuc, et al., 2012). Subtype3 (MYC-ampliﬁed MB) is characterized by 
amplification of MYC, loss of 5q and gain of chromosome1q and has the poorest 
prognosis. The frequency of this kind is about 25% (Northcott, Dubuc, et al., 2012). 
Subtype4 (heterogeneous) is characterized by loss of X chromosome and is more common 
in males and the prognosis is intermediate (Ransohoff, Sarin, & Tang, 2015) This subtype 
has the highest frequency of about 35% (Northcott, Dubuc, et al., 2012).  In the present 
thesis, I am mainly interested in aberrant Hh signalling with respect to MB, so the details 
would be limited to subtype2 (SHH-MB). 
 
 
 
 
WNT Subtype SHH Subtype
Subtype 3 Subtype 4
Figure G: The image shows frequency of Medulloblastoma molecular 
subtypes: WNT (~10%), SHH (~30%), Subtype 3 (~25%) and Subtype4 
(~35%). (Image adapted and modified from (Northcott, Dubuc, et al., 2012) 
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2.17 SHH-Subtype medulloblastoma 
  
 
The development of normal cerebellum is highly dependent on SHH signaling. The 
development of normal cerebellum occurs mainly post-birth, amidst which the Granule 
neuron precursors (GNP) multiply and eventually differentiate into granule neurons 
which constitute the most abundant cell kind in the brain. In vitro and in vivo studies have 
shown that GNP multiplication is mainly regulated by Shh which is derived from Purkinje 
cells (Vaillant & Monard, 2009). When the Shh ligand is absent, the GNPs do not multiply 
and directly migrate from external granule cell layer (EGL) to the internal granule cell 
layer (IGL) of the cerebellum during differentiation into granule neurons thereby 
producing a small cerebellum. In one of the research studies it was shown that when Shh 
signaling was blocked by using anti-Shh antibodies in chick cerebellum the size of the 
cerebellum decreased considerably, pointing the role of Hh signaling in development of 
normal cerebellum (Dahmane & Ruiz i Altaba, 1999). A number of signals play an active 
role in retaining the GNPs in the EGL during multiplication which include brain-derived 
neurotrophic factor (BDNF) and CXCL12 (Borghesani et al., 2002; Klein et al., 2001). 
Even though the secretion of Shh by purkinje cells is continued even after the 
development of cerebellum, the GNPs only react for a period of distinct time, pointing at 
other signaling pathways contributing to differentiation and migration. 
 
Nevertheless, uncontrolled Shh signaling due to mutations in the pathway lead to 
neoplasia. For example, Gorlin’s syndrome patients (also known as Nevoid basal cell 
carcinoma syndrome) have mutations in PTCH1 gene leading to continuous activation of 
the Hh pathway leading to tumors. These patients are predisposed to medulloblastoma 
and basal cell carcinoma (Johnson et al., 1996). The true role of this signaling pathway 
became evident when targeted Ptch1 mutations in mice lead to development of 
medulloblastoma (L V Goodrich, Milenković, Higgins, & Scott, 1997). Mutations in 
PTCH1 are the most prevalent kind of medulloblastomas arising in this subtype 
accounting for around 25-30% (PA Northcott et al., 2012). Apart from PTCH1 mutations; 
mutations in SMO, SUFU, amplification of SHH, GLI2 and MYCN can also be noticed in 
this subtype showing a clear link between SHH pathway and medulloblastoma (Jones et 
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al., 2012; Pugh et al., 2012; Robinson et al., 2012). The frequency of genetic 
abnormalities is tightly linked with age at diagnosis. Mutations in PTCH1 or SUFU are 
more common in infants and usually are carried in patient’s germline. More diverse 
molecular heterogeneity is seen in children with germline and somatic mutations in TP53 
together with PTCH1 mutations, MYCN, GLI2 and SHH amplifications. PTCH1 and 
SMO mutations can be seen more commonly in adult SHH-subtype medulloblastomas. 
(Kool et al., 2012). Chromosomal aberrations like loss of 17p,9q and 10q have been 
observed in this subtype (P A Northcott et al., 2012; Shih et al., 2014). Loss of PTEN and 
gene amplification of components of the Insulin like growth factor (IGF) signaling have 
also been observed. The frequency of disease is almost comparable in females and males, 
though slight higher tumor prevalence is seen in male infants (PA Northcott et al., 2012; 
Taylor et al., 2012). 
 
The SHH-subtype of medulloblastomas make up about 30% of all medulloblastoma cases 
(Kool et al., 2012). The current treatment includes chemotherapy, craniospinal irradiation 
and surgical resection (A. J. Gajjar & Robinson, 2014). Common chemotherapy 
procedures for MB include carboplatin, cisplatin, cyclophosphamide and vincristine 
among others but many side effects have been observed which include neurocognitive 
impairments, hearing loss, endocrine perturbations, cardiopulmonary problems and 
secondary malignancies (Fossati, Ricardi, & Orecchia, 2009). Recently, SMO inhibitors 
have shown encouraging results but demonstrate drug resistance due to mutations in SMO 
and have undermined the initial enthusiasm (Huang & Yang, 2015). 
 
The main therapeutic idea of modulating SMO in the hedgehog pathway came from the 
alkaloid cyclopamine which represses the Hh pathway (M. K. Cooper, 1998; Incardona, 
Gaffield, Kapur, & Roelink, 1998; Keeler, 1975). In many cancers cyclopamine has been 
shown to inhibit the growth of the tumors and it is also used for regulating the hedgehog 
pathway in cancer research studies. Hyperactivity of Hh signaling is one of the main 
reasons for basal cell carcinoma (BCC). It has been shown that use of cyclopamine 
diminishes 66% of UV-B induced BCC in Ptch+/- mice (Athar et al., 2004). Apart from 
BCC, cyclopamine has also been shown to be effective in suppressing medulloblastoma 
development in Ptch+/- mice  (Sanchez & Ruiz I Altaba, 2005). Due to poor oral solubility 
 35 
 
issues cyclopamine cannot be used in clinical development (Lipinski, Hutson, et al., 
2008). Several SMO inhibitors are being evaluated now like sonidegib (LDE-225), 
vismodegib (GDC-0449), LY2940680, PF-04449913 and BMS-833923 which are in 
advanced clinical trials (Amakye, Jagani, & Dorsch, 2013).  
 
One of the first SMO inhibitor, Vismodegib (GDC-0449) was approved by the U.S. Food 
and Drug Administration (FDA) for the treatment of metastatic or advanced Basal Cell 
Carcinoma (BCC). Vismodegib notably reduced the appearance of fresh BCC in treated 
individuals but led to reappearance upon stoppage of the drug (Huang & Yang, 2015). 
Apart from Vismodegib, HPI-1 and GANT61 are promising therapeutics which target 
Gli1 and Gli2 (Hyman et al., 2009; Lauth & Bergström, 2007; Mazumdar et al., 2011) 
whereas the drugs Saridegib, BMS-833923 and LDE-225 target SMO (Buonamici et al., 
2010; M. J. Lee et al., 2012). With respect to SHH medulloblastoma, Kool et al., (2014) 
explain that patients having mutations upstream of SMO, like PTCH1 or amplifications 
of SHH are good targets for SMO antagonists but patients exhibiting mutations 
downstream of SMO like NMYC and GLI2, would not react to drugs against SMO (Kool 
et al., 2014). Though the initial outcome of SMO inhibitors is promising in SHH driven 
medulloblastomas but quick drug resistance has been a challenge in treating the patients 
hence there is a need for development of new SMO inhibitors (Huang & Yang, 2015). 
 
 
2.18 Drug resistance in medulloblastoma 
 
 
Drug resistance in medulloblastoma has been quite a waffling issue. Different kinds of 
drug resistance mechanisms have been observed in medulloblastoma patients and have 
been linked to different number of genes (Huang & Yang, 2015). In one of the studies, it 
was demonstrated that radiation surviving medulloblastoma cells were evaluated for 
genes expressing stem cell behavior which is associated to the capability of a subset of 
tumor cells to incite metastasis or formation of tumor. In these cells, ATP-binding cassette 
(ABC) transporter ABCG2, which is related to drug resistance and stem cell behavior was 
seen to be highly elevated.  Radiation surviving cells from the patients when treated with 
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reserpine and verapamil which are ABC transporter inhibitors led to sensitization of cells 
to radiation (Ingram et al., 2013). Elevated amounts of ABCG2 are the characteristics of 
stem cells, and these transporters are involved in efflux of toxic substances from the cells 
which might include chemotherapeutic substances like drugs (Dean, Fojo, & Bates, 
2005).  
 
It was shown that cancer testis antigens (CTA) were found to be highly expressed in 
cancers like breast cancer and melanoma, these CTAs were also tested with respect to 
resistance to drugs in medulloblastoma. Expression of G antigen (GAGE) and melanoma-
associated antigen (MAGE) which belong to the CTA family of proteins, correlated to 
chemotherapeutic resistance. When these genes were inhibited, medulloblastoma cells 
became sensitized to etoposide and cisplatin (Kasuga et al., 2008). 
 
 
2.19 Mechanisms of resistance to SMO inhibitors 
 
 
In cancer therapeutic studies, acquired resistance is often a frequent phenomenon. 
Targeting SMO has been one of the key aspects in treating medulloblastoma but treating 
patients with acquired resistance against SMO inhibitors has been quite challenging. Four 
different acquired resistance mechanisms have been put forward in clinical as well as 
preclinical studies (Amakye et al., 2013).  
 
 
2.19.1 Resistance to SMO inhibitors due to mutations in SMO 
 
 
In one of the examples of acquired drug resistance to SMO inhibitors, a patient suffering 
with metastatic medulloblastoma displayed a missense mutation from G-to-C at 1697 
position (Aspartic acid to Histidine-D473H) in Smoothened drug binding pocket and 
thereby acquired resistance to drug GDC-0449 (Vismodegib).  In a mouse model 
alteration of the same amino acid has led to resistance against GDC-0449 (Vismodegib) 
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(Yauch et al., 2009). Apart from this particular mutation, mutations at D338N, N223D, 
D477G, L225R, G457S and S391N also render resistance to SMO inhibitors (Kieran, 
2014). In one of the studies with respect to BCC, resistance to SMO inhibition was 
demonstrated because of the mutation in SMO-G497W. Analysis of this mutation in silico 
further showed that it leads to conformational change thereby leading to blockage of 
protein drug entry site (Pricl et al., 2015) (Fig.H1).  
 
 
2.19.2 Resistance to SMO inhibitors via amplification of Gli2 
 
 
A second mode of resistance to SMO inhibitors in a Ptch-mutant medulloblastoma mouse 
model is via Gli2 amplification.  Gli2 amplification has been reported for both sonidegib 
and vismodegib resistance (Buonamici et al., 2010; Dijkgraaf et al., 2011). Gli2 
amplification correlated with increase in mRNA expression of Gli2 and negotiated 
growth of tumor in a Smo-independent way. Apart from this cyclin D which is one of the 
Hh target gene is also found to be amplified in tumors resistant to vismodegib likely 
providing another escape mechanism (Dijkgraaf et al., 2011) (Fig.H2). 
 
 
2.19.3 Resistance to SMO inhibitors via upregulation of PI3K-AKT pathway 
 
 
An alternate mechanism of resistance to SMO inhibitors is via PI3K-AKT pathway 
upregulation which was found by means of gene expression profiling studies in sonidegib 
sensitive vs resistant tumors (Buonamici et al., 2010).  The molecular events and players 
engaged in PI3K pathway upregulation and its link to GLI activation in resistant tumors 
is still enigmatic. The upregulation of PI3K pathway was seen in tumors both without and 
with amplification of Gli2 (Buonamici et al., 2010). The importance of compensatory 
PI3K pathway upregulation was shown by the capacity to overcome or delay the rise of 
resistance in medulloblastoma mouse models by combining BEZ235 (a dual mTOR and 
PI3K inhibitor) with sonidegib, everolimus (mTOR inhibitor) or buparlisib (BKM120; 
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PI3K inhibitor) (Buonamici et al., 2010). New reports suggest that crosstalk amidst PI3K-
mTOR and Hh signaling pathway along with SMO independent GLI signaling provide 
additional explanation for this combination (Riobó, Lu, Ai, Haines, & Emerson, 2006; Y. 
Wang et al., 2012) (Fig.H3).  
 
The current clinical trial study of buparlisib and sonidegib (NCT01576666) might give 
proof of concept of this treatment in related cancer types. Alternative ways which are 
worth exploring in combating acquired resistance involve inhibitors of SMO that are 
effective against resistant mutations and novel combinations with cilial translocation 
inhibitors or inhibitors of GLI transcription factors.  In one of the studies it was shown 
that Arsenic trioxide (ATO) which is a GLI inhibitor and itraconazole a cilial 
translocation inhibitor could suppress the growth of tumors in mouse medulloblastoma 
models exhibiting SMO-D477G resistance (J. Kim et al., 2013). In 23% of advanced basal 
cell carcinoma patients who are on continuous vismodegib treatment the mechanism of 
acquired resistance is still unknown (Atwood, Chang, & Oro, 2012; Chang & Oro, 2012).   
It would be useful to know if the lessons learned in BCC can be applied to MB or vice 
versa. 
 
 
2.19.4 Resistance to SMO inhibitors via upregulation of atypical protein kinase 
(aPKCɩ/λ) 
 
 
Atwood et al., (2013) demonstrated that atypical protein kinase (aPKCɩ/λ) is a GLI 
activator and described that in SMO inhibitor resistant human basal cell carcinoma the 
activity of aPKCɩ/λ is increased when compared to SMO inhibitor sensitive tumors.  
Blockade of this aPKCɩ/λ with the help of a myristoylated peptide blocker led to inhibition 
of mouse SMO inhibitor resistant basal cell carcinoma lines thereby providing an 
alternative path to overcome resistance to SMO inhibitors (Atwood, Li, Lee, Tang, & 
Oro, 2013) (Fig.H4). 
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Apart from these different mechanisms of SMO inhibitor resistance, it is also important 
to consider and investigate other pathways that are interacting with Shh signaling so that 
the components of these pathways can be used in context of combination therapy for 
medulloblastoma treatment (Huang & Yang, 2015). 
 
Figure H: Acquired resistance mechanism to inhibitors of SMO and ways to overcome resistance: (1) resistance via 
mutations in SMO. Resistance can be overcome by using SMO mutant, SMO translocation and GLI inhibitors. (2) via 
GLI2 Amplification, GLI inhibitor can be used for overcoming the resistance. (3) resistance via PI3-K-mTOR pathway 
upregulation, GLI and PI3KmTOR inhibitor can be used. (4) via upregulation of aPKCɩ/λ and inhibitor of aPKCɩ/λ can 
be used for overcoming resistance. (Image adapted and modified from Amakye et al., 2013) 
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2.19.5 p53  
 
 
Kool et al., (2014) observed that TP53 was elevated in pediatric medulloblastoma patients 
(4-17 ages) therefore further investigation is needed to ascertain the role of p53 in 
medulloblastoma. The status of p53 is critical for prognosis of Shh-medulloblastoma 
patients and also disease incidence. In one of the cohort studies, it was shown that TP53 
plays a pivotal role in survival status of Shh-medulloblastoma patients. They 
demonstrated that the five-year survival rates varied considerably between 41% to 81% 
in Shh-subtype medulloblastoma patients with and without TP53 mutations (Zhukova et 
al., 2013). In mice with single PTCH deletion, the prevalence of medulloblastoma was 
14%; this frequency rises to >95% in the presence of loss of p53, and this increase in 
frequency is specific for loss of p53 (Wetmore, Eberhart, & Curran, 2001). In one of the 
studies, it was observed that decreased MDM2 levels, a negative regulator of p53 led to 
reduced Gli1 and Gli2 expression besides small cerebella a distinct characteristic of 
decreased Shh signaling. Apart from this, Shh signaling in neuronal granule precursor 
cells stimulated accumulation of MDM2 and reduction of MDM2 blocked tumorigenesis 
in heterozygous PTCH mutant mice (Malek, Matta, Taylor, Perry, & Mendrysa, 2011). 
All of these observed results indicate that MDM2 interacts with Shh signaling and plays 
significant role in promoting medulloblastoma and for that reason MDM2 can be used as 
a possible target in combination therapy together with Shh signaling inhibitors in treating 
medulloblastoma (Huang & Yang, 2015). 
 
 
 2.19.6 Atoh1 & Boc 
 
 
Aberrations in Hh signaling or defects in the components of Hh signaling at the time of 
cerebellar development leads to medulloblastoma formation. Upon stimulation with Shh 
granule neuron precursors (GNPs) divide and exit the cell cycle and move towards the 
direction of cerebellum. Further, these cells start differentiating into neuronal granule 
cells in the internal granule layer (IGL) of the brain (Huang & Yang, 2015). The 
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transcription factor Atoh1 is crucial for this process, its expression is limited to 
proliferating GNPs and completely absent in IGL neurons. Atoh1 protein levels are 
stabilized by Shh signaling and achieved by blocking its proteasomal degradation via a 
phosphor-dependent process. Aberrant and continuous Shh signaling leads to elevated 
levels of Atoh1 thereby transforming GNPs to medulloblastoma cells (Forget et al., 
2014). It was demonstrated in one of the studies that Boc which is a Shh binding protein 
is upregulated in medulloblastomas. Apart from this, Boc inactivation led to decrease in 
proliferation and progression of early medulloblastoma to advanced stage cancer (Mille 
et al., 2014).  Atoh1 and Boc are both promising targets for combination therapy (Huang 
& Yang, 2015). 
 
 
2.19.7 Survivin 
 
 
Survivin deals with regulation of cell cycle and apoptosis inhibition (Sah, Khan, Khan, & 
Bisen, 2006). Brun et.al reported a crucial role for survivin in medulloblastoma tumor 
progression and proliferation. In their study, they described that PTCH mutant 
medulloblastoma cells expressed elevated levels of survivin. Isolated cells from survivin 
deleted medulloblastoma tumor cells from mice displayed significantly reduced 
thymidine incorporation together with cell cycle arrest in the G2/M stage (Brun et al., 
2015). Further studies are needed to delineate the role of survivin and its interaction with 
Shh signaling. Survivin might be a possible target in co-inhibition therapy for treating 
Shh driven medulloblastoma (Huang & Yang, 2015). 
 
 
2.19.8 bFGF (Basic Fibroblast growth factor) 
 
 
Basic fibroblast growth factor (bFGF) signaling seems to possess an inhibitory effect on 
Shh directed proliferation. In one of the studies, co-application of bFGF with Shh led to 
complete elimination of Shh-induced proliferation. Additionally, bFGF repressed the 
expression of Hh target genes like Gli1, Nmyc and Cyclin D1 (M. P. Fogarty, 
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Emmenegger, Grasfeder, Oliver, & Wechsler-Reya, 2007). Considering these effects of 
bFGF on Hh signaling, activating bFGF signaling might be an alternative approach in co-
targeting Shh-induced medulloblastoma  (Huang & Yang, 2015). 
 
Finally, patients belonging to the SHH-subtype of medulloblastoma should be treated 
with novel strategies due to existing heterogeneity and new therapeutic approaches should 
be developed for better treatment outcome. Recently, Pei et al., (2016) demonstrated that 
HDAC inhibitors together with PI3K inhibitors were able to inhibit the growth of MYC 
driven medulloblastoma (subtype 3) (Pei et al., 2016). Thinking in the same line HDAC 
inhibitors (HDACi) together with other SHH pathway inhibitors might bring about the 
same effect in SHH driven medulloblastoma. 
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3 Clinical significance and purpose of this study 
 
 
Hedgehog (Hh) signalling plays crucial roles in growth, development, cell fate, survival, 
pattern formation and regulation of several invertebrates and vertebrate organs (Varjosalo 
& Taipale, 2008). Abnormal Hh signalling during embryogenesis or in the midst of 
development may lead to severe disorders like polydactyly, skeletal malformations, 
craniofacial defects and holoprosencephaly (Hill, Heaney, & Lettice, 2003; McMahon, 
Ingham, & Tabin, 2003; Muenke & Beachy, 2000; Lu Zhang et al., 2006). It has also been 
reported that altered Hh signalling has been noticed in ciliopathies leading to syndromes 
like Bardet-Biedl syndrome, Polycystic kidney disease, Kartagener syndrome and retinal 
degeneration (Kyttälä et al., 2006; J Pan et al., 2005). Basal cell carcinoma (BCC, skin 
cancer) ( Hahn et al., 1996), medulloblastoma (MB) (Berman et al., 2002; L V Goodrich 
et al., 1997) and rhabdomyosarcoma (Kappler et al., 2004) can be caused by aberrant Hh 
signalling. Keeping in view the critical and diverse role/s played by Hh signalling, it is 
also important to treat, manage and cure diseases or disorders caused by aberrant Hh 
signalling. 
 
Medulloblastoma is one of the type of cancers caused by altered Hh signalling. It 
encompasses a collection of molecularly and clinically well-defined tumour subgroups 
that emerge from brainstem or cerebellum (Grammel et al., 2012; Louis et al., 2007; 
Taylor et al., 2012).  It is a neuroectodermal tumour affecting the cerebellum. Even 
though after development of impressive array of Hh antagonists drug resistance is still an 
unresolved problem that needs attention. The development of drug resistance is a frequent 
challenge in cancer drug therapy studies. It has been shown that mutations that are 
acquired in Hh pathway also lead to drug resistance and further challenges in treating the 
disease. In one of the examples of acquired drug resistance mechanism, a patient suffering 
with metastatic medulloblastoma displayed a missense mutation from G-to-C at 1697 
position (Aspartic acid to Histidine) in Smoothened drug binding pocket and thereby 
acquired resistance to drug GDC-0449 (Vismodegib). In one of the mouse models 
alteration of the same amino acid has led to resistance against GDC-0449 (Vismodegib) 
(Yauch et al., 2009). 
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The present study addresses the important role played by histone deacetylase (HDAC6) 
in Hh signalling and how one can use HDAC6 as a molecular drug target for future 
therapy against medulloblastoma.  It also opens new avenues for future drug molecules 
which are effective against this class of medulloblastomas. 
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4 Materials and Methods 
 
4.1 Materials 
 
4.1.1 Laboratory equipment and consumables 
 
 
Name Manufacturer 
Autoclave Fedegai Autuclavi Spa 
(Albuzzano, Italy) 
Block Thermostat QBD2 Grant Instruments (Cambridgeshire, UK) 
Blotting Paper 0,4mm thick                                    Hahnemühle FineARt GmbH, 
(Dassel,Germany)                                               
Cell culture plates 
(60x15mm,100x20mm,150x20mm)                      
Sarstedt (Nümbrecht, Germany) 
Cell scraper Sarstedt (Nümbrecht, Germany) 
 
Coverslips (25mm)                                              Thermo Fisher Scientific (Waltham, USA) 
Cryotubes Thermo Fisher Scientific (Waltham, USA) 
and Sarstedt (Nümbrecht, Germany) 
Cryobox (Cell freezing container) Thermo Fisher Scientific (Waltham, USA) 
Experion Automated Electrophoresis 
System 
BioRad (Hercules, CA, USA) 
Falcon tubes (15ml,50ml)  Sarstedt (Nümbrecht, Germany) 
Filter tips 10µl,1-20µl,20-200 µl,100-
1000µl 
STARLAB, GmbH (Hamburg, Germany) 
Finnpipette             Thermo Fisher Scientific (Waltham, USA) 
Fluorescence Microscope DMI3000B                     
with colour camera DFC300FX 
Leica (Wetzlar, Germany) 
Ice machine Ziegra (Isernhagen, Germany) 
Immobilon®- P Transfer Membranes                     Millipore (Billerica, MA, USA) 
LaminAir HA2448   Heraeus (Hanau, Germany) 
Leica DMR Fluorescence Microscope 
with Quantifire XI camera 
Leica (Solms, Germany) 
Intas (Göttingen, Germany) 
Mini-PROTEAN electrophoresis system BioRad (Hercules, CA, USA) 
Mini Trans Blot Cell tank blot system BioRad (Hercules, CA, USA) 
Multiwell plates for Cell culture                               
(6 well,12well, 24 well,48 well, 96 well)            
Greiner Bio-one, Kremsmünster, Austria 
Sarstedt, Nümbrecht, Germany 
Mx3000P/Mx3005P Qpcr system Agilent (Böblingen, Germany 
NanoDrop ND-1000 spectrophotometer Peqlab (Erlangen, Germany) 
Nunc™ MicroWell™ 96-Well Optical-
Bottom Plates with Polymer Base 
Thermo Scientific (Rochester, NY, USA) 
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Orion L microplate luminometer 
          
Berthold Detection Systems (Pforzheim, 
Germany) 
Parafilm Pechiney plastic packaging    
(Chicago, USA) 
Pasteur pipette Hirschmann Laboratory equipment                                                                           
(Eberstadt, Germany) 
 PP-microplate with flat bottom                               
(white 96-well)   
Greiner bio-one (Frickenhause, Germany) 
Serological pipette (5ml,10ml,25ml) Sarstedt (Nümbrecht, Germany) 
 
SRX-101A table top processor                       Konica Minolta (Wayne, NJ, USA) 
Super RX film                         Fujifilm (Tokyo, Japan) 
Syringe filter-0.2μm                        VWR (Radnor, USA) 
Tabletop Centrifuge Pico™ 17 
          
Thermo Fisher Scientific (Waltham, USA)       
 
Thermofast 96well qPCR plate non-
skirted with adhesive sealing sheets 
ABgene (Epsom, UK) 
Water bath Thermomix ME  
                                                                                 
B.Braun Melsungen AG (Melsungen, 
Germany) 
 
 
 
4.1.2 Chemicals 
 
 
Chemicals Manufacturer 
Absolute™ QPCR SYBR Green® 
Mix 
ABgene (Schwerte, Germany) 
Acrylamide mix (Rotipherose® 30%) Roth (Karlsruhe, Germany) 
APS AppliChem (Darmstadt, Germany) 
Beetle Juice PJK (Kleinbittersdorf, Germany) 
DMEM (High glucose) Invitrogen (Carlsbad, CA, USA) 
DMSO AppliChem (Darmstadt, Germany) 
DTT VWR (West Chester, PA, USA) 
Ethanol (Rotipuran; 99.8%; p.a.) Roth (Karlsruhe, Germany) 
FBS GOLD PAA (Pasching, Austria) 
Goat Serum (#G6767) Sigma-Aldrich (St.Louis, MO, USA) 
iScript™ cDNA synthesis kit Bio-Rad (Munich, Germany) 
PBS (1x) Invitrogen (Carlsbad, CA, USA) 
Penicillin/Sterptomycin(100x) PAA (Pasching, Austria) 
Trypsin/EDTA(1x) PAA (Pasching, Austria) 
2-Mercaptoethanol Sigma-Aldrich (St.Louis, MO, USA) 
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2-Propanol (HiPerSolvChromanorm) VWR (West Chester, PA, USA) 
Methanol VWR (West Chester, PA, USA) 
Milk powder Roth (Karlsruhe, Germany) 
NucleoSpin® RNA II Kit Macherey-Nagel (Dueren, Germany) 
PageRuler™ Prestained Protein 
Ladder 
Thermo Scientific (Waltham, MA, USA) 
Passive Lysis Buffer(5x) Promega (Fitchburg, WI, USA) 
Peirce ECL Western Blotting 
Substrate 
Thermo Scientific (Waltham, MA, USA) 
Saponin Fisher Scientific (Schwerte, Germany) 
SDS Roth (Karlsruhe, Germany) 
TEMED Sigma-Aldrich (St.Louis, MO, USA) 
TRIS Acros (Geel, Belgium) 
Triton X-100 AppliChem (Darmstadt, Germany) 
Vectashield® mounting medium with 
DAPI 
Vector labs (Burlingame, CA, USA) 
Water (HiPerSolv Chromanorm for 
HPLC) 
VWR (West Chester. PA, USA) 
Renilla Juice PJK (Kleinbittersdorf, Germany) 
 
 
4.1.3 Cell lines 
 
 
Cell lines Source of Cell lines 
ShhL2 ATCC 
Hek293A ATCC 
C3H10T1/2 ATCC 
NIH 3T3 ATCC 
MEF [ Smo*] Wade Bushman 
MEF Gli2dN Wade Bushman 
MEF Gli23 -/- Wade Bushman 
MEF [SHH] Wade Bushman 
MEF-WT R. Toftgård (KI, Huddinge, Sweden) 
MEF Sufu -/- R. Toftgård (KI, Huddinge, Sweden) 
 
 
4.1.4 Mouse lines 
 
The mouse  line Neuro2-SmoA1 was purchased from JAX (Stock number-008831) and 
has been described previously (Hallahan et al., 2004b). 
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4.1.5 Primary Antibodies 
 
 
Antibody Host species Clone Order No. Manufacturer 
Ac-H3 Rabbit  4499 Millipore 
Ac-αTub Mouse 6-11B-1 T6793 Sigma 
β-Actin Mouse AC-15  Sigma 
GLI1 Mouse  2643 Cell Signalling 
Technology 
GLI2 Goat  AF3635 R&D Systems 
GLI3 Goat  AF3690 R&D Systems 
HDAC6 rabbit  sc-11420 Santa Cruz 
HDAC6 rabbit  7558 Cell signalling 
Technology 
HIP1 goat  AF1568 R&D Systems 
Histone H3 rabbit  4499 Cell signalling 
Technology 
Lamin-B goat  sc-6217 Santa Cruz 
(α)-Tub mouse DM1A T6199 Sigma 
 
 
4.1.6 Secondary Antibodies 
 
 
Antibody Manufacturer Dilution 
Anti-goat-HRP Santa Cruz 1:3300 in 5% milk 
Anti-mouse-HRP NEB 1:3000 in 5% milk 
Anti-rabbit-HRP GE Amersham 1:6000 in 5% milk 
 
 
4.1.7 Short Interfering RNA(siRNA) Sequences (Targeting mouse genes) 
 
 
Name Target Sequence 
siGli1_1 GUAAUUACGUUCAGUCGCA 
siGli1_2 CCACAAGUCAAUAGCUAUA 
siGli1_3 GAAGUCCUAUUCACGCCUU 
siGli1_4 GUAACGCUCUGGACUCUCU 
siGli2_1 GGAGGGAAGGUACCAUUAU 
siGli2_2 CAUCAAGGCUCACACCGGU 
siGli2_3 GCAUCACGAUUCUCUAGUC 
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siGli2_4 GAUCAGAACACGCUAUACU 
siHdac6_1 UCUAGAGGGUGGAUACAAU 
siHdac6_2 UAAUGGAACUCAGCACAUA 
siHdac6_3 CAUCCAAGUCCAUCGCAAA 
siHdac6_4 GCGAAAGAGUAGGCACAAU 
siSmo_1 CCAAUUGGCCUGGUGCUUA 
siSmo_2 GAGCCCACCUCCAGUGAGA 
siSmo_3 GGGCAAGACAUCCUAUUUC 
siSmo_4 GAGGGUGGCCUGACUUUCU 
siCon (Targeting Firefly luciferase; 
siLuc) 
UAAGGCUAUGAAGAGAUAC 
siCon (Qiagen’s All-Star; siAll) AAUUCUCCGAACGUGUCACGU 
siCon (siMix) Equimolar mix of siUni, siAll, siLuc 
siCon (Sigma’s Universal neg. 
control#1; siUni) 
Proprietary 
 
 
 
4.1.8 qPCR Primer Sequences 
 
 
Gene Species Sequence (5’→ 3’) 
Foxj1 murine for: TTCTGCTACTTCCGCCATGCAGACC 
rev: TCATCCTTCTCCCGAGGCACTTTGA 
Gapdh murine for: GGTGTGAACGGATTTGGCCGTATTG 
rev: CCGTTGAATTTGCCGTGAGTGGAGT 
Gli1 murine for: CCCATAGGGTCTCGGGGTCTCAAAC 
rev: GGAGGACCTGCGGCTGACTGTGTAA 
Gli2 murine for: TGAGGAGAGTGTGGAGGCCAGTAGCA 
rev: CCGGGGCTGGACTGACAAAGC 
Gli3 murine for: AAAGCGGGAAGAGTGCCTCCAGGT 
rev: TGGCTGCTGCATGAAGACTGACCAC 
Hdac1 murine for: AGGAGGGAGAAGGTGGTCGCAAGAA 
rev: GCAGACCTTGCTCAGGCCAACTTGA 
Hdac2 murine for: CTGGGGACAGGCTTGGTTGTTTCAA 
rev: GTGTAGCCTCCTCCACCGAGCATCA 
Hdac3 murine for: ACCATGCACCCAGTGTCCAGATTCA 
rev: CATGGTCGCCATCATAGAACTCATTGG 
Hdac4 murine for: TTCCCAGGAAGTGGAGCACCAGATG 
rev: AAGGCTGCCAAGTACTCAGCGTCTCC 
Hdac5 murine for: TCGTCCTAGTCTCCGCTGGGTTTGA 
rev: TGTCATGAGCTGCCTGGTCAAGTGG 
Hdac6 murine for: TCCCTACAGCTTGGGGTTCTCAGCA 
rev: TCCCCAAATCCTTGTGTCAGCATCA 
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Hdac7 murine for: CTTTCTGTGGGCATCCTGGCTGAAG 
rev: AGGACCAGGGCTGACATCAGAGACG 
Hdac8 murine for: CCACCGAATCCAGCAAATCCTCAAC 
rev: TTCCACAAACCGCTTGCATCAACAC 
Hdac9 murine for: CTCGGGGTGGACAGTGACACCATTT 
rev: AGCCAGCTCAATGACACAGCCAACA 
Hdac10 murine for: GAGCCCAGTAGGGGGCCGAATTCTA 
rev: AGTGGCCTTCGAGAAAGGACCCAGA 
Hdac11 murine for: CCCAAGGCCCCCAACTTATCTCCTC 
rev: GCCTTGCCTTCTCTCCATCCTGGTC 
Hip1 murine for: TGGCTCCCATCGGCTCTTCATTCTA 
rev: AGGCTTAGCAGGCCCCTTTCGTCTC 
Hsd11b1 murine for: CGTGTCCATCACTCTCTGTGTCCTTGG 
rev: TCCTTGGGAGAAGCTTGGGCGTTAAT 
Ptch1 murine for: CGCCTTCGCTCTGGAGCAGATTTC 
rev: TGAGGAGACCCACAACCAAAAACTTGC 
Ptch2 murine for: CCCGTGGTAATCCTCGTGGCCTCTAT 
rev: TCCATCAGTCACAGGGGCAAAGGTC 
Rasl11b murine for: TCATCGGGGACTACGAACGAAATGC 
rev: ACTGCTCGCTGCAACTCAAGCCATT 
Rplp0 (P0) murine for: TGCACTCTCGCTTTCTGGAGGGTGT 
rev: AATGCAGATGGATCAGCCAGGAAGG 
GLI1 human for: TCTGGACATACCCCACCTCCCTCTG 
rev: ACTGCAGCTCCCCCAATTTTTCTGG 
PTCH1 human for: CCGCCTTCGCTCTGGAGCAGATT 
rev: TCTGAAACTTCGCTCTCAGCCACAGC 
RPLP0 (P0) human for: CCTTCTCCTTTGGGCTGGTCATCCA 
rev: CAGACACTGGCAACATTGCGGACAC 
 
 
4.1.9 Buffers 
 
       10x Blotting Buffer                    10x SDS Running Buffer 
 
 
 
                          
            Add H2O to 1l                         Add H2O to 1l 
                     Add 20% methanol when diluting 
 
 
Tris 30.3 
Glycine 144 
20% SDS 1.5ml 
Tris 30.3 
Glycine 144 
20% SDS 50ml 
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                         5x SDS Buffer                            10x TBS-T Buffer 
 
 
 
                                                       
 
 
                                                                                             Add H2O to 1l 
 
 
                    Running Gel Solution                                         Resolving Gel Solution 
 
 
 
                                                      
 
  
 
 
4.1.10 Software  
 
 
Software Manufacturer 
Adobe reader Adobe Systems Inc. San Jose, USA 
Image J 1.45s Wayne Rasband, National Institute of 
health, USA 
Leica LAS AF Lite Leica Microsystems, Wetzlar, Germany 
Microsoft office 2013 and 2016 Microsoft Corporation,USA 
Mx3000 Analysis software-version 4.10 Agilent Technologies, Santa Clara, USA 
Nanodrop 1000 measurement 
Version 3.7.1 
Thermo Fisher Scientific, Waltham, USA 
Prism5 and Prism6 GraphPad Software, La Jolla (USA) 
Mendeley Reference Manger-1.17.8 Elsevier (USA) 
Tris-HCl, pH 6.8 250 nM 
SDS 10% 
Glycerol 30% 30% 
2-Mercaptoethanol 5% 
Tris, pH-8 25 ml 
5M NaCl 30 ml 
Tween 20 1 ml 
Acrylamide Mix 4% 
Tris-HCl, pH 6.8 188mM 
SDS 0.1% 
APS 0.1% 
TEMED 0.01% 
Acrylamide Mix 7-15% 
Tris-HCl pH 8.8 188mM 
SDS 0.1% 
APS 0.1% 
TEMED 0.01% 
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4.2 Methods 
 
 
4.2.1 Cell Culture 
 
 
All the cell lines were cultured in Dulbecco’s modified Eagles medium (DMEM; high 
glucose plus glutamine and pyruvate; Invitrogen, Carlsbad, USA) supplemented with 
10% Fetal bovine serum (FBS Gold, PAA, Pasching, Austria) and 1% 
penicillin/streptomycin (PAA, Pasching, Austria) at 37o C with 5% CO2. Authentication 
of cell lines was performed by ATCC. All the MEF cell lines were regularly authenticated 
by functional testing (e.g., loss of Sufu in the case of Sufu-/- MEFs). Cell lines were also 
regularly tested for mycoplasma contamination. Sub-culturing of cells was done by 
washing the cells twice with DPBS and incubated with 1ml of trypsin/EDTA (PAA, 
Pasching, Austria) for 2mins and plated in new culture plates with fresh growth medium. 
 
 
4.2.2 Cryopreservation of Cells 
 
 
Adherent cells were washed once with 1xPBS and then 1ml of trypsin was added to the 
plate and incubated at 37oC for 2 mins. The trypsinized cells were resuspended in media 
and transferred to a sterile falcon tube and centrifuged for 5min at 1000 rpm at 4oC.After 
centrifugation the supernatant was removed with sterile pasteur pipette. The pelleted cells 
were quickly resuspended by adding 1ml of freezing media per vial  to be frozen. Now, 
the freezing media with cells were aliquoted into labelled cryovials and then placed in 
precooled cryobox later the vials were transferred to -80oC and finally to liquid N2 tank 
for long term storage. 
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4.2.3 Thawing of Cells 
 
 
The cells were removed from liquid Nitrogen (N2) tank and the vial was rapidly thawed 
at 37oC in water bath and immediately sprayed down with ethanol and placed in the 
laminar hood. The vial contents were immediately pipetted to a 50ml falcon containing 
prewarmed medium and centrifuged at 1000rpm for 5mins at 4oC. The pellet was 
resuspended in fresh prewarmed medium and pipetted into new 10cm dishes and 
incubated at 37o C with 5% CO2 untill  further subculturing. 
 
 
4.2.4 RNA Isolation 
 
 
Extraction of total RNA was performed using Nucleospin RNAII kit (Macharey-Nagel) 
according to manufacturer’s protocol. Elution of RNA was performed with 40μl RNase-
free H20 which was different to the protocol. The eluate was reapplied to the RNA column 
for re-elution. The purity and concentration of RNA extracted was photometrically 
determined using NanoDrop ND-1000 spectrophotometer (Peqlab). 
 
 
4.2.5 cDNA Synthesis 
 
 
Synthesis of cDNA was performed using iScript cDNA Synthesis Kit (Biorad) following 
the guidelines of manufacturer. In brief, 1μg of total RNA was diluted in 15μl of RNase-
free H20 and incubated with 4μl of iScript reaction mix and 1μl of iScript reverse 
transcriptase(RT) enzyme using the following protocol:  iScript TM 
 
Components Concentration 
iScript TM Reaction Mix 1 x 
iScript TM Reverse Transcriptase 1 μl 
RNA 1 μg 
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RNase free H2O ad 20μl 
 
Time Temperature 
5 mins     25o C 
30 mins 42o C 
5 mins 85o C 
∞ 4o C 
 
RNA and cDNA were stored at -20oC until further analysis. For cDNA synthesis (PTC-
200) Peltier Thermal Cycler, MJ Research, Quebec, Canada was used. 
 
 
4.2.6 Quantitative RT-PCR (qPCR) 
 
 
qPCR reactions were performed using 10μl of Absolute QPCR SYBR Green Mix 
(ABGene),0.4μl of forward primer(10μM), 0.4μl of reverse primer (10μM) and 8.2μl 
RNAase free H20. 1μl of cDNA was used for the qPCR reaction. qPCR reactions were 
performed in triplicates on 96-well qPCR plates (ABGene) using either the Mx3000p or 
Mx3005p qPCR systems(Agilent). The following protocol was used: 
   
Steps Time Temperature Cycle/s 
  Initialization  15 mins            95 o C 1 x 
  Denaturation 15 s 95 o C  
40 x 
 
    Annealing 20 s 65 o C 
    Elongation 15 s 72 o C 
 
  Melting curve 
60 s 95 o C  
1x 30 s 65 o C 
30 s 95 o C 
 
Results were calculated as relative mRNA expression(2ΔΔCt) and the data was obtained 
from at least three independent experiments and are shown as the mean ± SD. 
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4.2.7 RNAi Transfection  
   
 
Cells were plated subconfluently and transfection was performed by using 35nmol/L 
siRNA (Dharmacon SMART pools) on day0 using Lipofectamine RNAiMAX 
(Invitrogen) as transfection reagent. On day1 the cells were confluent and the siRNA 
solution was replaced with full growth medium. Cells were further grown for another 48 
hours and RNA was isolated on day3. 
 
 
4.2.8 Luciferase reporter assays 
 
 
Cells were plated in triplicates and allowed to grow to full confluency in solid white 96-
well plates having clear bottom. Consequently, the media was replaced with full growth 
medium with 100nmol/L SAG along with the indicated compounds for 2 days. Later, the 
cells were lysed with Passive Lysis Buffer (Promega) and Firefly and Renilla luciferase 
activities were measured by using an Orion L microplate luminometer (Berthold 
Detection Systems) with the help of Beetle and Renilla Juice reagents (PJK; 
Kleinblittersdorf, Germany). The measurement was taken for 5seconds after 2 second’s 
time delay. 
 
 
4.2.9 Osteogenic Differentiation Assay 
 
 
Cells were plated in triplicates and allowed to grow to full confluency in 96-well plates. 
Consequently, the cells were treated with compounds in full growth media for 4 days. 
Later, the cells were lysed with Passive Lysis Buffer (Promega). The lysate was divided 
into two parts; one part was used to measure the alkaline phosphatase(AP) activity 
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(Alkaline Phosphatase Blue Micro well Substrate; Sigma) and the other part was used for 
quantification of protein (Bio-Rad Protein Assay; Bio-Rad). 
 
 
4.2.10 Immunofluorescence 
 
 
The cells were grown sub-confluently on etched glass cover slips (25mm diameter, 
Thermo Scientific). Cells were washed gently with 1x PBS and then fixed in 4% 
formaldehyde/PBS for 10mins at room temperature (RT). The cells were then washed 
twice with 1xPBS at room temperature for 5mins. For permeabilization 0.5% Triton-
X100/PBS was used for 5min at RT. Later, the cells were blocked with 10% serum and 
0.1% saponin and incubated for 2hrs at RT.The cells were washed once with PBS at RT 
for 10 mins. Primary antibodies were diluted in 50μl PBS (per cover slip) containing 
10%serum and 0.1% saponin and incubated overnight at 4oC. After washing twice with 
1xPBS at RT for 5mins, the cells were incubated with secondary antibody conjugated to 
fluorophores diluted in PBS containing 10%serum and 0.1% saponin at room temperature 
in the dark for 2hrs. Later, the cells were washed twice with 1xPBS for 5mins and the 
cells were rinsed with millipore H2O. Finally, the cells were mouted on glass plates using 
Vectashield® mouting medium with DAPI (4’6-Diamidino-2-Phenylindole).  
 
 
4.2.11 Immunohistochemistry 
 
 
Paraffin embeded and formaldehyde-fixed tissue sections were used for 
immunohistochemistry and then treated with HDAC6 antibody (1:50 ) from Santa Cruz 
Biotechnology(sc-11420). 
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4.2.12 Cilia formation assay 
 
 
Cells were plated in low (1%) serum and the compounds were added immediately. Later, 
the cells were stained with cilia specific antibodies and cilia were counted after 48hrs 
under the microscope. 
 
 
4.2.13 Cilia resorption assay 
 
 
Cells were plated in low (1%) serum. After, 24 hrs the compounds were added in media 
containing 1% FBS and the cells were stained with cilia specific antibodies and then 
counted under the microscope. 
 
 
4.2.14 SDS PAGE and Immunoblotting 
 
 
The cells were lysed in 400-500μl of SDS loading buffer according to the cell density and 
plate format. The lysates were then boiled at 95oC for 5 mins and stored at -20oC. The 
lysates were seperated using the Mini-PROTEAN electrophoresis system (Bio-Rad) for 
SDS PAGE. 25μl to 30μl of lysates per lane and 10μl of  prestained protein ladder were 
loaded. Seperation of proteins was performed at 10mA in stacking gel and 30mA in the 
running gel. After seperation of gels, the gels were blotted on Immobilon®- PVDF tansfer 
membranes (Millipore) by using Mini Trans-Blot® cell tank blot system (BioRad). 
Blotting was done for 90 min at 350 mA. Later, the blots were blocked in 5% milk/TBS-
T for atleast 2hrs and then incubated with primary antibody at 4oC overnight. The blots 
were washed three times for 10 mins in TBS-T, then the membranes were incubated with 
HRP-conjugated secondary antibodies for 2hrs at room temperature which was followed 
by washing the blot for three times for 10 mins at RT.  Detection of the signal was 
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performed by using Pierce ECL western blotting substrate (Thermo Scientific) according 
to the manufacturer’s protocol. Luminescence was visualized by exposing the blots to 
Fuji Medical RX films and developing using SRX-101A table top machine (KONICA 
MINOLTA). 
 
 
4.2.15 Microarray 
 
 
RNA was isolated from MEF [SHH] cells using Nucleospin RNAII kit (Macharey-Nagel) 
according to manufacturer’s protocol. The RNA integrity was determined using the 
Experion Automated Electrophoresis system (Bio-Rad). The isolated RNAs from two 
different experiments were pooled in a 1:1 ratio. Labelling, hybridization and analysis of 
data was done by the Genomics core facility of IMT (Institute of Molecular Tumour 
Biology, University of Marburg). Labelling of RNA was performed with the two-colour 
Quick-Amp Labelling kit(Agilent) and hybridized against Agilent-026655 microarrays. 
For normalisation of microarray data “loess” method was used implemented in marray 
package of Bioconductor/R. Probes from Agilent were assigned to the Ensembl 
revision70 genome annotations by aligning sequences with a short-read aligner (Bowtie 
against both, the genome and the transcriptome) as described previously (Adhikary et al., 
2011). The data obtained from microarray has been deposited at Array express under the 
number E-MTAB-2440. 
 
 
4.2.16 Compound Soubilization 
 
 
First the compounds were dissolved in 100% DMSO at a concentration of 70mg/mL. 
Later, the compounds were diluted in 45% (2-hydroxypropyl) -b-cyclodextrin (Sigma 
#332607) in PBS to get a final concentration of 5mg/mL (1mg/200mL). All animal 
studies were in approval with institutional and federal state laws. 
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4.2.17 Statistical Analysis 
 
 
All the data shown here are the mean of three independent experiments (unless indicated 
otherwise) ±SD. Calculation of statistical significance was done by applying two-tailed 
Student t test (Microsoft Excel). *, P < 0.05; **, P< 0.005; *** P < 0.0005. Unless stated 
otherwise, the comparison is between experimental and corresponding control (si Con, 
DMSO). 
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5 Results 
 
 
5.1 In Murine Medulloblastoma HDAC6 is overexpressed 
 
 
It has been demonstrated earlier that HDAC6 plays an important role in etiology of many 
different cancers and in the biology of primary cilium (Jacob et al., 2011; Y. S. Lee et al., 
2008b; Pugacheva et al., 2007; Sakamoto & Aldana-Masangkay, 2011; Santo et al., 2012) 
which made me to look into the role of HDAC6 in Hh-driven medulloblastoma.  
Consistent with a previous report (S. J. Lee et al., 2013), I observed endogenous Hdac6 
to be overexpressed in cerebellar tumours arising in SmoA1model. In this SmoA1 mouse 
model the Shh signaling pathway was precisely activated in precursors of cerebellar 
granule neurons, which was accomplished by constitutively expressing the active form of 
Smo gene SmoA1 under the control of the NeuroD2 (Neurogenic differentiation 2) 
promoter that is expressed particularly in cerebellar granule cells; Fig.1A; (Hallahan et 
al., 2004b; Hatton et al., 2008). Protein expression of HDAC6 in wt animals can be seen 
mostly in non-tumor Purkinje cells. Contrastingly, granule cell-derived tumour cell nests 
show high immunoreactivity to HDAC6 (Fig.1B) in the transgenic mice. These 
observations raised the question regarding functional role for HDAC6 in Hh driven 
medulloblastoma. 
 
 
 
 
 
 
 
Figure1: In Medulloblastoma mouse model HDAC6 is overexpressed.  A, Expression of Hdac6 mRNA in cerebellae 
of wt mice (~ 4 months old; n=9) and from cerebellae of medulloblastoma mice (SmoA1 mice, n=9). B, 
Immunohistochemistry of HDAC6 on paraffin-embedded sections from wt cerebellum (left) and cerebellum from 
SmoA1 medulloblastoma (middle and right). Note: In wt,the purkinje cells (and not the granule cells in the Internal 
Granule cell Layer) show the highest HDAC6 signal (indicated by arrowheads, brown), whereas in medulloblastoma 
SmoA1 the cancerous granule cell nests show the highest HDAC6 expression. 
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5.2 Active Hh signalling is blocked by pharmacological HDAC6 inhibitors 
 
 
To address the importance of HDAC6 in Hh-induced disease, I first investigated the role 
of this enzyme in the Hh pathway. For this, I used specific and three structurally distinct 
HDAC6 antagonists (Tubacin, CAY-10603, and ACY-1215), which had been 
characterized and described before (Fig. 2A; (Haggarty, Koeller, Wong, Grozinger, & 
Schreiber, 2003; Kozikowski, Tapadar, Luchini, Ki, & Billadeau, 2008; Santo et al., 
2012)). I used these inhibitors to treat fibroblasts as they are one of the major Hh-
responsive cell types known and also, they represent a good model system for the analysis 
of Hh signaling pathway. As demonstrated in Fig. 2B, analysis of ShhL2 cells (NIH 3T3 
fibroblast cells which carry a Hh-responsive luciferase construct in their genome stably), 
shows that induction of Hh pathway by synthetic agonist (SAG; (J. K. Chen et al., 2002) 
could be dampened by co-applying HDAC6 inhibitors in increasing amounts. The 
blockade of HDAC6 and its negative effect on endogenous Hh signaling could be seen 
with all the three compounds pointing against unspecific off-target effects. To preclude 
the effects of the compounds on ciliogenesis negatively, in compound treated cells I 
analyzed the presence of primary cilia. In line with earlier reports, HDAC6 helps in 
stabilizing rather than destabilizing cilia (Jacob et al., 2011; Pugacheva et al., 2007) I 
could not find any change in ciliary morphology or significant reduction of ciliogenesis 
in cells treated with HDAC6 inhibitors, regardless of serum concentrations used 
(Supplementary Fig. S1A-S1C). Apart from this, inhibition of HDAC6 did not lead to 
gross cytotoxicity (Supplementary Fig. S2A). To analyze further, I checked the effect of 
inhibition of HDAC6 on Hh driven physiologic process. C3H10T1/2 cells, which are 
mesenchymal progenitor cells differentiate along osteogenic lineage upon treatment with 
Hh, a process that can be visualized by staining for Alkaline phosphatase (AP) activity, 
which is an osteogenic marker protein. As demonstrated in Fig. 2C and D, the treatment 
with HDAC6 inhibitors CAY-10603 or Tubacin potently antagonized the SAG-induced 
differentiation of C3H10T1/2 cells. Interestingly, SMO induced cell differentiation was 
blocked by TSA (a pan-HDAC inhibitor), but also led to an increase of basal induction 
(Fig. 2D). However, to validate the need of HDAC6 in Hh signaling with a chemical 
compound free approach, I selectively knocked-down endogenous Hdac6 mRNA with 
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the help of a pool consisting of four different siRNAs (si Hdac6) constructs in MEF cells 
stably transfected with SHH (MEF[SHH]; (Lipinski, Bijlsma, Gipp, Podhaizer, & 
Bushman, 2008)) Transfection of siHdac6 in these constitutively signaling cells led to a 
clear reduction of expression of the established Hh target genes Gli1, Ptch1, and Ptch2; 
suggestive of Hh pathway inhibition (Fig.2E and F). I investigated individual siRNAs 
present in the pool and could demonstrate that except one, three other RNAi sequences 
inhibited Hh signaling, in line with my earlier findings (Supplementary Fig.S2B). In 
addition, the siRNA pool specific for Hdac6 did not lead to reduction in the expression 
levels of other Hdac family members but only Hdac6 (Supplementary Fig. S2C), 
confirming that the noticed effects are indeed due to particular interference with Hdac6.  
Furthermore, siRNA targeting Hdac6 signiﬁcantly inhibited SAG- induced osteogenic 
differentiation in C3H10T1/2 cells (Supplementary Fig. S2D-S2F). Lastly, action of 
HDAC6 was vital for Hh signaling regardless of the serum concentration used (10% FBS; 
see Fig. 2; 1% FBS; see Supplementary Fig. S3A) and the nature of the ligand (see 
recombinant SHH instead of SAG in Supplementary Fig. S3B). Collectively, my data 
demonstrates that HDAC6 operates in the Hh pathway and is needed to attain full pathway 
activity. 
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Figure 2: Hh signalling is impaired by targeting endogenous HDAC6. A, HDAC6 inhibitors chemical structure used 
in this study.B, Reporter luciferase assay using ShhL2 cells. The respective compound concentrations are shown in 
[mmol/L] following the drug, for example, SANT_0.2 indicates 0.2mmol/L of the SMO antagonist SANT-1 (positive 
control),C,C3H10T1/2 osteogenic differentiation assay.SAG was used to activate Hh signalling which induces 
osteogenic differentiation, shown by the blue AP staining. HDAC6 inhibitor/s treatment interferes with this process.D, 
Osteogenic differentiation assay result quantification  shown in C. The mean (±SD) of three biological independent 
experiments is shown. Note: TSA (pan-HDAC inhibitor ) blocks nuclear HDAC activity resulting in AP induction even 
in the absence of SAG.E, qPCR measurement of Hh target gene expression in (Gli1, Ptch1, and Ptch2) in MEF[SHH] 
cells transfected with indicated siRNA. RNAi against Gli2 was used as positive control. *, P < 0.05; **, P < 0.005; 
***, P < 0.0005.F, verification of knockdown of Hdac6 mRNA in MEF [SHH] cells via siRNA.b The inset shows 
functional depletion of HDAC6 protein indirectly: transfection with siHdac6 leads to increase in the levels of acetylated 
tubulin (Ac. Tub). The endogenous HDAC6 protein expression levels were too low to be detected by Western blotting 
using MEF cell lysates. 
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5.3 Epistatic investigation of HDAC6 effects 
 
 
Next, I was keen to know at which stage in the Hh signal transduction pathway the 
function of HDAC6 would be integrated. For this purpose, I used MEF cell lines that 
contain activating alterations to trigger Hh signaling at various levels of the pathway and 
measured the extent of Hh target genes Gli1, Hip1, Ptch1 and Ptch2. As demonstrated in 
Fig. 3A and B signaling in MEF[SHH] cells (which stimulate Hh signaling at ligand step) 
could be inhibited by treatment of different HDAC6 antagonists as shown at the mRNA 
(Fig. 3A) and protein level (Fig. 3B). Once again, neither of the HDAC6 inhibitors used 
notably led to increase in the levels of acetylated histone H3 (Fig. 3B and Supplementary 
Fig. S2G), in comparison with Trichostatin A (pan-HDAC inhibitor) arguing for HDAC6-
selective mechanisms. Interrupting endogenous HDAC6 activity also inhibited Hh 
signaling in Ptch1-/- MEFs (Supplementary Fig. S3C) and in MEF[Smo*] (cells stably 
expressing a dominant active version of Smo); Fig. 3C; (Lipinski, Bijlsma, et al., 2008).  
 
In spite of the fact that blockade could be seen in all cell lines, it looked as if cells bearing 
wt Smo (i.e., MEF[SHH] and Ptch1-/- MEFs) were more effectively inhibited than cells 
with mutant Smo MEF[Smo*]. Additionally, in Ptch1-/- cells I observed Hip1(Hh target 
gene) expression was strongly inhibited only if TSA (a pan HDAC inhibitor) was used 
(Supplementary Fig. S3C). On the other hand, HDAC6 inhibitors and SANT led to a 
modest reduction in Hip1 levels pointing indirectly to HDAC6 antagonists having no 
profound result on acetylation of histone as demonstrated earlier. To know if HDAC6 
also plays functional role downstream of Smo and Ptch1, I took advantage of MEF cells 
bearing genetic deletion of Sufu gene, leading to strong, but ligand- and receptor-
independent constitutive signaling (A. F. Cooper et al., 2005; Svärd et al., 2006). Despite 
the ineffectiveness of SANT (SMO-selective inhibitor) (J. K. Chen et al., 2002) in these 
cells, inhibition of HDAC6 by ACY-1215, CAY-10603 or Tubacin led to inhibition of 
Hh target gene expression, although not alike as in MEF[SHH] cells (Fig. 3D).  
 
Further, confirmation for inhibition of pathway in Sufu-/- cells was also seen upon 
knockdown of Hdac6 via RNAi (Supplementary Fig. S3D). Lastly, I employed cells with 
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stable expression of low amounts of an activated mutant of GLI2, the transcription factor 
determining the terminal steps of the Hh signaling pathway MEF[Gli2dN] cells; 
(Lipinski, Bijlsma, et al., 2008). As demonstrated in Fig. 3E blockade of HDAC6 also 
inhibited Hh target gene activity in these cells, whereas SANT the upstream inhibitor was 
inactive. Once more the repression attained by blockade of HDAC6 was not as marked 
as in cells with Hh pathway activation at ligand step (e.g., MEF[SHH]). Considering that 
nuclear HDACs are involved in direct deacetylation and activation of GLI (Canettieri et 
al., 2010), I was curious to know if identical process applied to HDAC6 too. In Hh 
luciferase reporter assays the activity of transfected GLI1 was promoted significantly by 
HDAC1 and HDAC2, HDAC6 remained inactive, despite marked protein expression 
levels (Fig. 3F).  
 
This outcome shows that HDAC6 does not act possibly through deacetylation of the GLI1 
transcription factor directly and probably works in an indirect way. In conclusion, I 
summarize that HDAC6 regulates Hh signaling positively, likely at two different steps: 
first, at the receptor level (PTCH1/SMO), and second, at a downstream point in the 
signaling pathway at the level of transcription factors. 
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Figure3: HDAC6 epistatic analysis in the Hh cascade. Qpcr analysis of Hh target gene expression (Gli1, Ptch1 and 
Ptch2) in cells treated for 48 hours to different inhibitors (SANT, 0.2 mmol/L; ACY-1215, 10 mmol/L; CAY-10603, 4 
mmol/L; Tubacin, 20 mmol/L; TSA, 0.5 mmol/L). A, Expression of Hh target genes in MEF[SHH] cells. B, Analysis of 
protein expression in MEF[SHH] treated with the indicated compounds via western blotting. Note that nuclear histone 
H3 acetylation is increased only by treatment with TSA but not with HDAC6 inhibition with CAY-10603 or Tubacin. 
C, Expression of Hh target genes in MEF[Smo*] cells. D, Expression of Hh target genes in Sufu-/- MEF cells. E, 
Expression of Hh target genes in MEF[Gli2dN] cells.  F, Hh reporter assay in Hek293T cells transfected with various 
(Flag-tagged) HDAC constructs or HA-GLI1 plus empty vector control (mock). The Western blot analysis shows the 
protein expression of HDAC proteins in this assay. *, P < 0.05; **, P < 0.005; ***, P < 0.0005; ns, not signiﬁcant. 
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5.4 Global investigation of HDAC6 blockade 
 
  
After having noticed the opposing effects of inhibition of HDAC6 in distinct Hh assays, 
I was keen to examine the broad impact on the Hh-activated transcriptome. For this 
purpose, I treated MEF[SHH] cells with RNAi directed against Hdac6 or with control 
siRNA (targeting Fireﬂy luciferase, siLuc). As reference constructs, I employed siRNA 
directed against Gli1, Gli2 or Smo. RNA isolated from these cells was used in microarray 
analysis. To correlate differences in global expression pattern between siHdac6 and 
siSmo transfected samples, scatter plot was used to show the data. On the grounds of 
noticed changes in gene expression, I grouped the transcripts into eight distinct classes, 
namely: (1) si Smo: down; siHdac6: up, (2) si Smo: no change; siHdac6: up, (3) si Smo: 
down; siHdac6: up, (4) si Smo: down; siHdac6:no change, (5) si Smo: up; siHdac6:no 
change, (6) si Smo: down; siHdac6: down, (7) si Smo: no change; siHdac6: down, (8) si 
Smo: up; siHdac6: down. These eight classes can be noticed as color coded dots on the 
scatter plot in Fig. 4A.  
  
To explore the behavior of these genes, a subsequent comparison was done with siGli1/2 
conditions, the transcripts were transferred (and their respective color) into siGli1/2 
scatter plots (Fig. 4A, middle and right). Correlation of the expression differences induced 
on siHdac6 and siSmo transfection disclosed that, as predicted, the established and well-
known canonical Hh target genes (e.g., Ptch1/2) come into group 6 (Fig. 4A, left, purple 
dots) and were down regulated by both the siRNAs. Not surprisingly, regulation of these 
genes was in the same way by siGli1/2 (purple and pink dots in Fig. 4A, middle & right). 
Intriguingly, genes that were governed in opposite directions by siSmo and siHdac6 
(groups 8 and 1, brown and orange colored dots) were fundamentally absent. Further, an 
intriguing bunch of genes fell into group7 and was down regulated by siHdac6, but was 
not influenced by siSmo. Anyhow, a considerable part of these genes (red-colored dots 
in Fig. 4A) was shifted to the left in siGli1/2 plots, signifying that they were governed by 
Gli factors and Hdac6, but not by Smo. Lastly, group of genes exist that were not 
regulated by Hdac6 but were governed by Smo (groups 5 and 4 (gray and green spots) in 
Fig. 4A). Interestingly, a sizable fraction of these genes was not governed by either 
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Gli1/2. Considering that not all the Smo-governed genes were influenced by Gli1 and 
Gli2 (and vice versa), I assigned typical set of genes termed as the “Hh signature.” This 
gene set accomplished the following rigorous criteria: genes must have been (i) regulated 
in siSmo samples to that of siControl and (ii) Additionally, siSmo-controlled genes had 
to be governed in the same way by either siGli1/2 transfection. This led to a group of 
genes consisting of 820 transcripts ("Hh signature"). Analyzing the Hh gene signature 
with that of the genes regulated upon Hdac6 knockdown uncovered 56% of the Hh 
signature were influenced by loss of Hdac6 (Fig. 4B). The obtained expression data were 
verified by qPCR analysis of exclusive genes shown to be regulated by only “Gli1” and 
by "Gli1 and Hdac6". As demonstrated in Fig.4C, in MEF[SHH] cells the canonical 
hedgehog target genes namely Ptch1, Ptch2, and Hip1 all of them were down regulated 
by siHdac6 as well as by siGli1 transfection. In comparison, the expression of Rasl11b, 
Foxj1 and Hsd11b1 were particularly influenced by Gli1, but not by Hdac6, showing that 
Hdac6 influences a sub group of Gli target genes, as shown by the microarray experiment. 
 
In summary, function of HDAC6 affected more than half of the genes involved in the Hh 
signature, but did not influence all the Hh signature genes. Strikingly, HDAC6 also have 
an effect on the regulation of genes, which are Smo-independent yet Gli-dependent, 
pointing at some amount of downstream pathway regulation by HDAC6 (Dhanyamraju 
et al., 2015). 
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Figure 4: Global gene expression analysis. A, scatter plot representation showing mRNA expression changes in 
MEF[SHH] cells transfected with shown siRNA sequences (e.g., si Smo_P indicates four different siRNA pools 
targeting Smo). Left, Comparison between siHdac6 and si Smo samples. Genes fall under eight different color-coded 
sections based on their change in expression. Due to defined cutoff of at least two-fold the center of the scatter plot is 
empty. Middle, comparison between siHdac6 and siGli1 samples. Genes are shown on the left.nc, no change. B, Venn 
diagram showing MEF[SHH] microarray data categorized into "Hh signature," "Smo-regulated," and "Hdac6-
regulated" genes. By definition, there is a full overlap between the Hh signature and the Smo-regulated gene set. C, 
Verification of expression data derived from microarray experiment via quantitative real-time PCR in A. MEF[SHH] 
cells were used. 
 
 
5.5 HDAC6 and its dichotomous effect on Hh signaling 
 
To know more about the main molecular association between Hh and HDAC6, I 
concentrated on GLI2 and GLI3; the key downstream signal transducers in the pathway. 
Since HDAC6 had been shown to play role in degradation of protein and clearance  
(Bazzaro et al., 2008; Cyril Boyault et al., 2006, 2007; Hebron et al., 2013; J.-Y. Lee et 
al., 2010; Pandey, Batlevi, Baehrecke, & Taylor, 2007). 
 
I asked if inhibition of HDAC6 would alter the levels of protein or processing of GLI2/3. 
Reduction of overall amounts of GLI2 full-length protein including the amount of GLI3 
activator (GLI3A) and repressor (GLI3R; Fig. 5A) was observed upon treatment of 
NIH3T3 fibroblasts with inhibitors of HDAC6; ACY-1215 and CAY-10603. At the level 
of mRNA, expression of Gli2 was reduced, but the levels of Gli3 mRNA was stable (Fig. 
5B). These results imply that HDAC6 takes part in GLI3 protein stabilization and also 
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plays a role in transcriptional control of Gli2 expression (Knockdown experiments of 
siHdac6 and/or knockout studies of Hdac6 would throw further light on impact of Hdac6 
on Gli3 protein stabilization and its role in transcriptional control of Gli2 expression). 
 
Considering that inhibition of HDAC6 decreased the GLI3R form, I hypothesized that 
this could lead to derepression of Hh target gene expression in unstimulated cells. 
Consequently, I examined expression of Gli1 in wt MEF cells treated with HDAC6 
inhibitors. As demonstrated in Fig.5C, treatment with HDAC6 inhibitors ACY-1215 or 
CAY-10603 certainly activated the Hh pathway even in the absence of SAG or Hh ligand. 
The observed target gene expression could not be reverted by the co-application of SANT 
(SMO antagonist), which was capable of blocking SAG- induced signaling (Fig. 5C). 
Contrary to the latter finding but in agreement with my earlier observations (Figs. 2 and 
3), inhibition of HDAC6 also decreased the maximal target gene expression induced by 
SAG. Comparable data were seen when Ptch1 expression was determined 
(Supplementary Fig. S4).  
 
Furthermore, the increase in the levels of Gli1 transcription by inhibitors of HDAC6 could 
also been shown at the protein level in non-stimulated cells. In accordance with the qPCR 
results (Fig. 5C), blockade of HDAC6 led to a decrease of maximal protein levels of GLI1 
in SAG-induced cells (Fig. 5D). To ascertain if the increase in Hh signaling by antagonists 
of HDAC6 was negotiated via GLI factors or via GLI independent mechanisms, I 
employed cells with impaired functional Gli2 and Gli3 genes (double knockout Gli23-/-
MEFs;(Lipinski, Bijlsma, et al., 2008)). Treating these cells with inhibitors of HDAC6 
disclosed that increase of Gli1 observed in wt cells was notably decreased in the absence 
of Gli2 and Gli3 (Fig.5E), implying specifically that HDAC6-mediated effects on the 
protein levels of GLI3R might be crucial. Regardless, positive effects mediated via Gli1 
may be required for ligand-independent Hh gene activation as well. 
 
Consequently, I decreased endogenous Gli1 amounts by RNAi based knockdown of the 
residual Gli1 expression in Gli 23-/- cells. As demonstrated in Fig.5F, transfection with 
siGli1 decreased the Hh target gene activation (Ptch1 and Ptch2) in comparison to 
siControl cells, arguing also for the need of Gli1 activator function (Fig. 5F). Altogether, 
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I noticed a dichotomous role of HDAC6 inhibitors on Hh signaling pathway. On one 
hand, inhibition of HDAC6 leads to reduction of maximal Hh target gene activity; while 
on the other, HDAC6 interference activates basal target gene transcription. I speculate 
that the first effect may be caused due to the decreased Gli2 mRNA expression upon 
exposure to HDAC6 inhibitors, whereas the latter observation possibly involves the 
decreased GLI3R protein together with GLI1 activator functions. 
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Figure 5: Molecular connection between Hh signalling and HDAC6. A, top, Expression of endogenous Gli2A (full-
length Gli2) in NIH3T3 cells. As a loading control Actin was used. Bottom, Protein expression of endogenous Gli3A 
(full-length Gli3) and Gli3R (truncated repressor form) expression in NIH3T3 cells treated with the indicated 
compounds for 2days (ACY-1215,10mmol/L; CAY 10603,4mmol/L; SANT,0.2mmol/L; SAG,0.1mmol/L) B, 
Expression of Gli2 and Gli3Mrna in NIH 3T3 cells treated with indicated compounds for 2days ACY-1215, 10 mmol/L; 
CAY-10603, 4 mmol/L; SANT, 0.2 mmol/L) C, Expression of Gli1 mRNA in wt MEFs treated with the indicated 
inhibitors(concentrations as in A) D,  Expression of endogenous Gli1 protein in wt MEFs treated with  indicated 
compounds (concentrationsasinA;TSA,0.5mmol/L) E, Expression of Gli1 mRNA in wt MEFs in comparison with Gli1 
expression in Gli23-/- MEFs, both treated with shown inhibitors(concentrations as given in A). The samples were set to 
1 for comparison. F, Expression of Ptch1and Ptch2 mRNA in Gli23-/- MEFs transfected with siRNA controls or with 
siRNA against Gli1. Cells were treated with DMSO or with 10 mmol/L ACY-1215 for 2 days. The inset depicts an 
immunoblot confirming the Gli1 knockdown in these cells. *, P < 0.05; **, P < 0.005. 
 
 
5.6 Inhibition of HDAC6 pharmacologically has repressive effects on growth of in 
vivo medulloblastoma 
 
 
Next, I was interested to investigate whether an HDAC6 directed approach could in 
principle be exploited as a future therapy option in the treatment of medulloblastoma. To 
investigate this matter, I treated primary mouse medulloblastoma cells (MB99-1cells 
derived from the SmoA1 mouse model; (Hallahan et al., 2004a; Hatton et al., 2008) with 
increasing amounts of HDAC6 inhibitors in culture and measured live cells by the help 
of Cell Titer assays (Fig. 6A-C). As demonstrated in Fig. 6A-C, I noted marked decrease 
in cell number upon 2 days of HDAC6 inhibition that correlated with increase in 
acetylation of tubulin [r2 = 0.927 (ACY-1215) and r2 = 0.989 (CAY-10603) for inhibition 
of cell growth vs acetylation of tubulin]. The observed cytotoxicity was seen in mouse 
medulloblastoma cells. Notably, and in accordance with my earlier data, acetylation of 
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histone was not increased by inhibitors of HDAC6 used and did not correlate with 
inhibition of growth [r2= 0.377 (ACY-1215) and r2= 0.686 (CAY-10603) for inhibition 
of cell growth vs. acetylation of histone H3; Fig. 6A-C]. These data provoked me to 
investigate the in vivo effects of HDAC6 inhibition via small molecules.  
 
For this purpose, I took s.c. allografts from primary SmoA1 medulloblastoma cells 
(MB99-1 cells). For the generation of s.c. allografts, SmoA1 medulloblastoma primary 
cells were retrieved directly by shearing and mincing the tumor portions. Later, these cells 
which were obtained from the cerebellum were mixed in a ratio of 1:1 with Matrigel and 
introduced subcutaneously into C57BL/ 6J mice for expansion. Eventually, after few 
cycles of this in vivo passaging, cells were collected and combined with Matrigel (1/3rd 
of the volume) and introduced subcutaneously into 15 C57BL/ 6J mice (Bai, Staedtke, 
Rudin, Bunz, & Riggins, 2015; Metcalfe et al., 2013; G. Y. Wang et al., 2011) which 
were 3.5 months old and weighed 20g. After 7 days, all the injected mice had perceptible 
subcutaneous tumors of around 25mm2. This procedure was performed mainly to generate 
adequate tumor possessing mice for drug treatment and analysis (Metcalfe et al., 2013). 
After tumors, had reached a perceptible volume, mice (in groups of 5) were injected peri 
tumoral s.c. with ACY-1215 or solvent or with 50 mg/kg of either Vismodegib (GDC-
0449, an FDA-approved SMO antagonist as a positive control).  Control (solvent-treated) 
tumors increased greatly in size over a 12-day period, while ACY-1215 and Vismodegib 
treated tumors remained small (Fig.6D). This was also seen in the mean tumor weight of 
dissected tumors taken at the end of the experiment (Fig.6E). Markedly, no signs of 
toxicity were seen and all the drugs were well tolerated by animals.    
 
Analysis of the tumor tissue immunohistologically disclosed that ACY-1215-treated 
tumors particularly had elevated levels of cleaved caspase-3, a sign of apoptosis (Fig. 6F), 
in spite of the fact that both the drugs (ACY-1215 and Vismodegib) repressed activity of 
Hh pathway in the in vivo allografts, measured by decreased Hh target gene activity 
(Supplementary Fig. S5). 
 
 
 
 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:  In vivo effects of HDAC6 inhibition pharmacologically. A, immunoblot from MB-99 cells treated with 
indicated compound concentrations for 2 days.  Note that tubulin acetylation is affected by HDAC6-selective inhibitors 
but histone H3 acetylation is not affected, whereas TSA (the pan HDAC inhibitor) increases both B and C, quantified 
results shown in A. In addition, the data contain figures on cell growth (CellTiter assay; Promega) measured after 2 
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days of incubation with indicated compounds. D, in vivo allograft: tumor volume change relative to day 0 (volume ¼ 
100%). Shown is the mean of 5 mice, E, mean tumor weight (g) of resected allografts on day 12. F, cleaved caspase-3 
immunohistochemistry (brown) on allograft tissue sections taken on day 12. SOL, solvent; VIS, Vismodegib; ACY, 
ACY-1215. *, P < 0.05; **, P < 0.005. 
 
 
 
 
5.7 Analysis of HDAC6 expression using publicly available datasets 
 
 
To further strengthen my observations and data, I took advantage of publicly available 
databases. For this purpose, I used R2 (http://r2.amc.nl) which is a Genomics and 
visualization platform developed by Jan Koster from the department of Oncogenomics, 
Academic Medical Center (AMC), Netherlands. Firstly, I analyzed the expression of 
HDAC6 in seven different human medulloblastoma datasets deposited in R2 database; 
namely Kool (62 samples), delattre (57 samples), Pfister (223 samples), den Boer (51 
samples), Hsieh (31 samples), Pfister (73 samples), Gilbertson (73 samples) altogether 
containing 570 samples (Fig.7A). Though the expression of HDAC6 was seen in all the 
seven human medulloblastoma datasets, it should be mentioned that there was quite a 
variation between and within the datasets and a particular dataset could not be associated 
with higher or lower expression of HDAC6. In all the graphs, the cross mark on the top 
represent outlier/s at the higher end of expression and cross mark under represent outlier/s 
at the lower end of expression.   
 
Next, I went on to check the expression of HDAC6 in four different mouse 
medulloblastoma datasets in R2 database; Roussel (64-samples), Finkelstein (16-
samples), Morrissey (42-samples), Rowitch (27-samples) (Fig.7B). Also, in these four 
mouse medulloblastoma datasets the expression of HDAC6 was quite variable but the 
highest HDAC6 expression was observed in samples from Finkelstein dataset. It was 
previously shown by Lee et al., (2013) that HDAC6 expression was higher in tumor 
medulloblastomas ( Lee et al., 2013) and also recently Dhanyamraju et al., (2015) have 
demonstrated higher HDAC6 expression in SmoA1 mouse medulloblastoma model. 
Further, I was interested to know if HDAC6 is expressed more in mouse or human 
medulloblastomas, for that I compared HDAC6 expression between human 
medulloblastoma datasets (Fig.7A) and mouse medulloblastoma datasets (Fig.7B). 
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Among the two datasets HDAC6 expression was found to be slightly higher in human 
medulloblastoma datasets when compared to that of mouse medulloblastoma datasets.  
  
After, this I was keen to know the expression of HDAC6 in different medulloblastoma 
molecular subgroups (Wnt group, Shh group, Group 3 and Group 4). For this, I chose five 
datasets (molecular classification available only for these five datasets) based on the 
molecular classification of medulloblastoma, namely Gilbertson (73 samples- Fig.7C), 
Pfister (223-samples- Fig 7D), Northcott (103 samples- Fig 7E), Shirsat (19 samples- Fig 
7F) and Cavalli (763 samples-Fig 7G). HDAC6 expression could be seen in all the four 
subgroups and in all the five datasets but it was quite variable. Upon close observation, I 
could see HDAC6 expression slightly higher in Group 4 belonging to Gilbertson (Fig 7C), 
Pfister (Fig 7D), Shirsat (Fig 7F) and Cavalli (Fig.7G) datasets but the same could not be 
seen in Northcott dataset (Fig 7E). 
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Figure 7: Analysis of HDAC6 expression using publicly available datasets. (A) HDAC6 expression in seven different 
human medulloblastoma datasets with a total of 573 samples (Kool-62-samples, delattre-57-samples, Pfister-223-
samples, den Boer-51-samples, Hsieh-31-samples, Pfister-73-samples, Gilbertson-73-samples). (B) HDAC6 
expression in four different mouse medulloblastoma datasets with a total of 149 samples (Roussel-64 samples, 
Finkelstein-16 samples, Morrissey-42-samples, Rowitch-27-samples). (C, D, E, F, and G) HDAC6 expression in four 
different medulloblastoma subtypes (Wnt group, Shh group, group3 and group4) from five different human 
medulloblastoma datasets (C-Gilbertson-73 samples, D-Pfister-223 samples, E-Northcott-103 samples, F-Shirsat-19 
samples, and G-Cavalli-763 samples with a total of 1181 samples). Cross mark (x) on the top represent outlier/s at the 
higher end of expression and cross mark under represent outlier/s at the lower end of expression. 
 
 
 
 
 
 
 
 
 
 
 78 
 
6 Discussion 
 
 
HDAC6 belongs to class IIb family of HDACs. HDAC6 is predominantly localized to 
cytoplasm due to the presence of NES (Nuclear export signal) and SE14 motifs (C 
Boyault et al., 2007; de Ruijter et al., 2003). HDAC6 functions as HSP90, cortactin and 
α tubulin deacetylase. HDAC6 has been demonstrated to play cardinal role in formation 
of immune synapse, cell spreading and migration, degradation of misfolded proteins and 
stress granules (SG). It has also been shown that it takes part in viral infections by forming 
complexes with distinct protein partners (Yingxiu Li et al., 2013). The primary substrate 
of HDAC6 is α tubulin by which it modulates vesicular transport and microtubule 
dynamics (S. Chen, Owens, Makarenkova, & Edelman, 2010; Jim P Dompierre et al., 
2007; Zilberman et al., 2009). HDAC6 is involved in modulation of diverse signalling 
pathways such as TGF-β-Notch pathway (Deskin, Lasky, Zhuang, & Shan, 2016), 
RAS/MAPK signaling cascade (Sakamoto & Aldana-Masangkay, 2011), ERK-MAPK 
signal transduction pathway among others. It has also been demonstrated that HDAC6 
plays an important role in Hh signaling pathway (Dhanyamraju et al., 2015). HDAC6 
plays a critical role in misfolded protein clearance by autophagy or via generation of 
aggresomes (Delcuve et al., 2012). Furthermore, HDAC6 plays important role as a 
modulator of gene transcription (P. B. Chen et al., 2013; Ozaki, Wu, Sugimoto, Nagase, 
& Nakagawara, 2013; Palijan et al., 2009; Westendorf et al., 2002). 
 
 
Keeping in view the plenty of functions in which HDAC6 is engaged, it is startling to 
note that Hdac6 null mice are healthy and viable and exhibit a subtle phenotype (Yu 
Zhang et al., 2008). In the present study, I observed HDAC6 to be overexpressed in Hh-
initiated medulloblastoma and I speculated if HDAC6 plays a functional role in this 
pathway. Indeed, HDAC6 overexpression has been seen in medulloblastoma before, 
however no connection to the Hh signalling pathway was made. In publicly available 
datasets, the expression of HDAC6 in mouse medulloblastoma was also found to be high 
(Fig.7B). Interestingly, these authors saw no impact of Tubastatin, a known HDAC6 
inhibitor on granule cell proliferation or allograft growth ( Lee et al., 2013), which 
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considerably may be due to low concentrations used. Higher concentrations of HDAC 
inhibitors were required for prominent Hh inhibition in my hands pointing that full 
blockage of HDAC6 is needed to affect the Hh system. In spite of using higher 
concentrations of inhibitor, the compounds particularly inhibited HDAC6 but displayed 
no marked effect on histone acetylation levels. I should bring up that, my allograft system 
suffers from its synthetic nature and that direct compound injections can possibly lead to 
high local inhibitor concentrations, still I tried to bypass the issue by altering the injection 
sites and by not directly injecting into the tumour. It is vital to specify here that modern 
HDAC6 inhibitors can pass through the blood-brain barrier and consequently be tested 
under more physiological settings in autochthonous medulloblastoma mouse models in 
future (Jochems et al., 2014). Interestingly, these modern HDAC6 inhibitors have been 
shown to carry antidepressive characteristics, an aspect that have been linked to Hh 
inhibition in the past (Lauth et al., 2010).  
 
 
Altogether, my data provides insight into HDAC6 and its role in Hh signalling, on one 
hand HDAC6 is needed for full pathway activation. Secondly, HDAC6 is required for 
complete repression of target gene expression under basal Hh signalling levels in the 
absence of ligands. This complicated interaction between negative and positive functions 
may explain the subtle phenotype in Hdac6 knockout mice. It has been demonstrated by 
Zhang et al (2008) that mice deficient in Hdac6 are normal, fertile and viable. Increase in 
global tubulin acetylation was found in these mice. Hdac6 knock out mice displayed 
slight increase in bone mineral density and mild defective immune response. Moreover, 
in differentiation assays using C3H10T1/2 cells and in reporter assays with ShhL2 cells 
induction of ligand-independent Hh signalling was not seen indicating either cell type 
difference or that the HDAC6 activated derepression of Hh target genes is not adequately 
strong enough for some biological processes to occur.  
 
 
However, it is important to point out that in the allograft model, mice getting Vismodegib 
a SMO antagonist presented with alopecia (hair loss) at the cutaneous injection sites 
(Supplementary Fig. S6). Indeed, this is not surprising as Hh signalling is well known to 
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promote hair growth. The hair loss observed in mice treated with Vismodegib was not 
seen in the ACY-1215 treated group, regardless of the fact that the Hh pathway was 
blocked. Analysis of microarray data revealed that about half of the SMO/GLI-regulated 
genes are also influenced by HDAC6 and one of the probable reason for no hair loss might 
be that HDAC6 does not influence or play role in affecting the Hh target genes needed in 
hair cell biology. The said observation needs further investigation as it might be used to 
prevent undesirable side effects related to blocking of Hh-dependent physiological 
mechanisms. Further, an unanswered question at present is if HDAC6 inhibition 
influences SMO-dependent, but GLI-independent noncanonical signalling (Bijlsma, 
Damhofer, & Roelink, 2012; Chinchilla, Xiao, Kazanietz, & Riobo, 2010).  I speculate 
that the effect of HDAC6 on Hh signalling might be a result of acetylation of tubulin and 
is not due to direct deacetylation of GLI proteins by HDAC6.  
 
A number of tubulin post translational modification have been demonstrated which 
include acetylation, phosphorylation, polyglycylation, polyglutamylation, polyamination, 
detyrosination and deglutamylation (Janke, 2014). For example, it has been shown that 
HDAC6 is involved in deacetylation at Lys-40 of α-tubulin (Hubbert et al., 2002). 
Recently, Liu et.al, (2015) mapped lysine acetylation sites on tubulin by a mass 
spectrometry (MS) method. They compared acetylated peptides from HDAC6 knockout 
mice and wild-type mice and identified six new deacetylation sites on α-tubulin (K370, 
K60 and K394) and β-tubulin (K58, K154 and K103) which are likely carried by 
HDAC6 thereby adding new list of sites deacetylated by HDAC6. This would further 
strengthen our knowledge of how HDAC6 is able to regulate multiple cellular functions 
and microtubule stability.(N. Liu et al., 2015). 
 
 
Tubulin post translational modifications have been shown to influence microtubule based 
motor protein-driven transport. As Hh signalling depends very much on IFT transport 
toward and from the primary cilia (Corbit et al., 2005; Dorn, Hughes, & Rohatgi, 2012; 
D Huangfu et al., 2003), meddling with these mechanisms may, consecutively, inhibit the 
specifically coordinated Hh signalling. Intrinsically, sustained and elevated levels of 
tubulin acetylation may functionally look like defects in cilia like those normally induced 
 81 
 
by loss-of- function of IFT components (Loss of important IFT components like Ift88 and 
Kif3a which are involved in IFT transport and involved in ciliogenesis lead to elevated 
levels of post translational modifications including hyper-acetylation of microtubules, 
high levels of α-tubulin acetyl-transferase activity and altered microtubule stability 
(Berbari et al., 2013) ). In fact, certain aspects of my HDAC6 related data shown here, 
such as ligand-independent activation of pathway and reduced GLI3R levels are 
consistent with previously reported defects on cilia (Cervantes, Lau, Cano, Borromeo-
Austin, & Hebrok, 2010; Han et al., 2009; Haycraft et al., 2005; Ho et al., 2013; Wong et 
al., 2009). Shi et al., (2015) showed that centrosomal protein of 70kDa (Cep70) is 
involved in stability of microtubules by increasing acetylation of tubulin and via 
interacting with HDAC6. Cep70 interacts with HDAC6 in cytoplasm and colocalizes with 
it. Using pulldown experiments and immunoprecipitation they demonstrated that Cep70 
interacts with HDAC6 physically via the amino terminal peptide fragment that 
accommodates the coiled-coil domains and the amino terminal Cep70 fragment is needed 
for regulating tubulin acetylation. They also reason that Cep70 by binding to deacetylase 
domains of HDAC6 might inhibit the deacetylase activity thereby increasing the levels 
of acetylation of tubulin and stability of microtubules. It would therefore be of interest to 
know if Cep70 is involved in ciliogenesis via regulating HDAC6 or via modulating 
acetylation of tubulin (Shi et al., 2015).In Sufu-/- cells, in which signalling is independent 
of cilium (M. H. Chen et al., 2009; Jinping Jia et al., 2009), inhibition of HDAC6 
negatively impacts Hh pathway, pointing that other intracellular transport mechanisms 
perhaps are needed downstream of primary cilia and SMO. An alternative picture would 
be that the nuclear HDAC6 fraction may impinge on transcriptional complexes 
controlling Hh target gene expression, such as Gli2 transcription. Principally, I could 
show the specificity of the compounds for HDAC6 at multiple instances in my work. 
Firstly, induction of Hh pathway with the help of SAG (which is smoothened agonist) in 
ShhL2 could be blocked by using HDAC6 specific inhibitors namely ACY-1215, Tubacin 
and CAY-10603. The blockage of Hh signaling with all three inhibitors points at the 
specificity of these inhibitors and rule against off-target effects (see figure 2B). I go on to 
show in a physiologic process driven by Hh, differentiation of mesenchymal progenitor 
cells; C3H10T1/2 cells into osteogenic lineage by SAG could be inhibited by usage of 
Tubacin and CAY-10603 (see figure 2C and D). Interestingly, SMO activated cell 
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differentiation was blocked by pan HDAC inhibitor TSA but also led to an increase in 
basal induction of Alkaline phosphatase activity (see figure 2D) suggesting that nuclear 
HDAC family members suppress basal Hh signaling and further highlights the precision 
of the HDAC6 inhibitors used in the study.  Further, I used MEF[SHH] cells which 
stimulate Hh signaling pathway at the ligand step. In these cells Hh signaling pathway 
could be inhibited by using different HDAC6 antagonists (Tubacin, ACY-1215, CAY-
10603) which could be determined by measuring Hh target genes (Gli1, Ptch1 and Ptch2) 
at the mRNA level (see figure 3A) and at the level of protein (GLI1, HIP1) (see figure 
3B). Once more, neither of the used HDAC6 inhibitors led to increase in the levels of 
acetylated histone H3 (see figure 3B and supplementary figure S2G) in comparison to 
TSA arguing for HDAC6-selective mechanisms. Further, I used MEF[Smo*] which 
expresses dominant active version of Smo (see figure 3C) and Ptch1-/- MEFs (see figure 
S3C) in which blockade of endogenous HDAC6 activity by ACY-1215, CAY-10603 and 
tubacin led to decrease in Hh signaling pathway which was determined by measuring the 
target gene levels of Gli1, Ptch1 and Ptch2 in MEF[Smo*] and Gli1, Ptch2 and Hip1in 
Ptch1-/- MEFs. Additionally, in Sufu-/-MEFs which signal constitutively independent of 
ligand and receptor HDAC6 inhibition with ACY-1215, Tubacin and CAY-10603 led to 
inhibition of Hh target gene expression namely Gli1, Ptch1and Ptch2 (see figure 3D). 
Lastly, I used MEF[Gli2dN] cells which stably express low amounts of an activated 
mutant of GLI2, the principal transcription factor determining the terminal steps in Hh 
signaling pathway. Even in these cells HDAC6 inhibition with ACY-1215, Tubacin and 
CAY-10603 led to inhibition of Hh target genes; Gli1, Ptch1 and Ptch2 (see figure 3E). 
In conclusion, I could show the specificity of HDAC6 inhibitors in different cell lines and 
the effect of HDAC6 inhibitors on Hh signaling pathway. Recently, it has been 
demonstrated that at immunologic synapse cilia-like processes play important role (de la 
Roche et al., 2013), a cellular structure that had been linked to HDAC6 previously 
(Serrador et al., 2004). However, additional data is required to show the function of 
HDAC6 in immunologic synapse-triggered Hh signalling.  
 
In several tumours HDAC6 has been shown to possess oncogenic activity (Aldana-
Masangkay et al., 2011; Gradilone et al., 2013; Jochems et al., 2014). Due to these 
findings and the need of HDAC6 to obtain maximal Hh signalling, I investigated the in 
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vivo effect of an HDAC6-based therapy in an allograft model of medulloblastoma. 
Blockade of HDAC6 displayed marked outcome with respect to survival of 
medulloblastoma cells and was as potent as Vismodegib (positive control) in vivo. 
Considering that ACY-1215 (not with Vismodegib) led to extensive and robust apoptosis, 
prolonged exposure to the treatment might even lead to eradication of tumor completely. 
 
It should be mentioned here that ACY-1215 (ricolinostat) the HDAC6 specific inhibitor 
is presently under second phase of clinical trials for treatment of patients with lymphoid 
malignancies and multiple myeloma. Apart from ACY-1215, ACY-241 which is also a 
HDAC6 specific inhibitor is into phase-I clinical trials for treatment of multiple myeloma 
(S.N.Batchu, et al., 2016). The advantage of ACY-1215 over other known inhibitors is 
that it is less toxic to T-cells and mononuclear cells in blood (Santo et al., 2012). Most of 
the knowledge on ACY-1215 has been from combination therapy where it is used along 
with inhibitors of proteasome like bortezomib (Amengual et al., 2015; Dasmahapatra et 
al., 2014; Mishima et al., 2015; Santo et al., 2012). The complication involved with 
proteasome inhibition is it leads to misfolded protein accumulation in aggresomes and it 
is speculated that blockage of aggresome formation via inhibition of HDAC6 may bring 
about more synergistic benefit together with inhibition of proteasome (S. N. Batchu et al., 
2016). In a mouse model of multiple myeloma, combination therapy consisting of ACY-
1215 and bortezomib improved survival and delayed growth of tumor (Santo et al., 2012). 
The same effect was also seen in a diffuse large B-cell lymphoma xenograft model 
(Amengual et al., 2015). In another study, ACY-1215 along with carfilzomib (proteasome 
inhibitor) inhibited formation of aggresomes and led to increased apoptosis in multiple 
myeloma cells (Mishima et al., 2015). It has also been shown that, for the treatment of 
multiple myeloma ACY-1215 has been used together with immunomodulatory drugs 
(IMiDs)  (T Hideshima et al., 2015). Two immunomodulatory drugs pomalidomide and 
lenalidomide are under clinical evaluation.  In the same lines, it has been demonstrated 
that ACY-241 is presently undergoing clinical evaluation and is in phase I a/b for 
treatment of refractory multiple myeloma. It is used as a monotherapy or as a combination 
therapy with low-dose dexamethasone or pomalidomide (S. N. Batchu et al., 2016).  
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Though the most prominent HDAC6 inhibitors have been Tubastatin A, ACY-1215 and 
Tubacin, several other inhibitors of HDAC6 have also been developed like hydroxamic 
acids having aryl alanine which are effective at very low micromolar concentrations 
(Schäfer et al., 2008, 2009). Lately, many different molecules based on thilolate (Itoh et 
al., 2007), mercaptoacetamide (Kozikowski et al., 2007), sulfamide (Wahhab et al., 
2009),  and trithiocarbonate (Dehmel et al., 2008) are being developed which can 
specifically inhibit HDAC6. The major issue with HDAC inhibitors is most of the 
inhibitors are built on common structural basis hence have broader activity and not very 
specific for a particular HDAC. Inks et al (2012) screened a library containing 1280 
compounds and identified five novel molecules having HDAC inhibitory activities. One 
of the identified molecules was NSC-95397 which was selective for HDAC6. Based on 
the structure of NSC-95397 several daughter compounds were synthesized and one such 
compound was NQN-1 which inhibited HDAC6 at 5.5μM concentration and had 
minimum inhibitory effect on other HDACs (Inks, Josey, Jesinkey, & Chou, 2012). 
 
Keeping in view the diverse biological roles played by HDAC6 it is not unexpected that 
it is involved in various diseases like neurodegenerative diseases, cardiovascular, kidney 
diseases and mood disorders among others (S. N. Batchu et al., 2016). For example, it has 
been demonstrated in a neurodegenerative disease model of Drosophila, spinal bulbar 
muscular atrophy (SBMA), when ubiquitin-proteasome system (UPS) was impaired, 
HDAC6 aided in compensatory autophagy (Pandey, Nie, et al., 2007).  
 
 
HDAC6 has also been shown to play a role in Parkinson’s disease (PD). Loss of cells 
producing dopamine and accumulation of Lewy bodies (abnormal aggregates of protein) 
which are mainly composed of α-synuclein protein are the characteristics of Parkinson’s 
disease. HDAC6 in Drosophila assists in formation of inclusion bodies and secures 
dopaminergic neurons from the damaging effects of α-synuclein (Du et al., 2010) and 
lewy bodies are highly enriched for HDAC6 in brain section of patients suffering from 
PD (Kawaguchi et al., 2003). Taken together these data indicate that upregulation of 
HDAC6 in PD might be a protective response indirectly implying that inhibition of 
HDAC6 therapeutically may slow down disease progression (Yan, 2014).  
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Huntington’s disease (HD) is another neurological disease in which HDAC6 has been 
shown to play a role. HD is caused due to expansion of glutamine repeat sequence in the 
huntingtin gene, this also leads to protein aggregation and misfolding of protein (Hatters, 
2008). It has been shown that the resultant mutant protein incites neuronal toxicity via 
destabilization of microtubules (Trushina et al., 2003). Inhibition of HDAC6 in HD might 
lead to increase in α-tubulin acetylation and thereby improved neuronal transport (J. P. 
Dompierre et al., 2007; Guedes-Dias et al., 2015). Charcot-Marie-Tooth disease (CMT) 
is another example where inhibition of HDAC6 have shown positive results. Progressive 
muscle wasting and loss of sensation are the characteristics of CMT. In one of the 
subtypes of CMT, known as CMT2 missense mutations in gene coding for heat shock 
protein 27 has been shown (HSPB1) (Evgrafov et al., 2004) which leads to reduced α-
tubulin acetylation and axonal transport defects upsetting peripheral nerves. Treatment of 
mice having mutations in HSP27 with Tubastatin-A reversed the axonal transport defects 
(d’Ydewalle et al., 2011).  
 
 
The role of HDAC6 in Alzheimer’s disease (AD) is being studied comprehensively (Ling 
Zhang, Sheng, & Qin, 2013). The most important character of AD is the generation of 
neurofibrillary tangles that are composed of aggregates of hyper-phosphorylated Tau 
protein (Mandelkow & Mandelkow, 1998). The aggregation and phosphorylation of Tau 
protein into aggresomes is principally dependent on SE14 of HDAC6 and Tau 
microtubule binding domain (Ding, Dolan, & Johnson, 2008). It has been reported that 
Tau is HSP90’s client protein (Karagöz et al., 2014) and the levels of HDAC6 correspond 
to tau protein burden and a reduction in the expression levels of HDAC6 favoring tau 
protein clearance possibly through inducing acetylation of HSP90 (Cook et al., 2012). 
HDAC6 null mutation in Drosophila salvaged tau induced defects of microtubule (Xiong 
et al., 2013). Apart from this the levels of HDAC6 were high in postmortem brain tissue 
samples from Alzheimer patients (Ding et al., 2008). Recently, two different groups have 
demonstrated cognition improvement in mouse model of Alzheimer’s disease upon 
inhibition of HDAC6 (Selenica et al., 2014; Ling Zhang et al., 2014). Though a number 
of studies show HDAC6’s role in Alzheimers disease, its precise role is not yet clear (Sri 
N Batchu et al., 2016). Apart from neurodegenerative diseases HDAC6 has also been 
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shown to be associated with mood disorders. For example, it has been demonstrated that 
functional loss of HDAC6 in rodents has antidepressant kind of effect (Espallergues et 
al., 2012; Fukada et al., 2012; J. B. Lee et al., 2012). One of the plausible reason for this 
might be that HDAC6 is involved in negotiation of glucocorticoid receptor and HSP90, 
inhibition of HDAC6 or knockdown inhibits receptor translocation to the nucleus in 
neuronal cells  (Espallergues et al., 2012). Recently, two specific and novel brain 
penetrating HDAC6 inhibitors ACY-775 and ACY-738 were demonstrated to exhibit 
exploration-enhancing effects in mice (Jochems et al., 2014). 
 
It has been shown that HDAC6 is involved in cystic diseases in both kidney (Mergen et 
al., 2013) and liver (Gradilone et al., 2014). For example, in polycystic kidney disease 
(PKD), PKD1 mutations lead to HDAC6 upregulation which ultimately leads to growth 
of cysts. Tubacin treatment inhibited proliferation of cystic cells, reduced the levels of 
cyclic AMP and activated cystic fibrosis transmembrane conductance regulator (CFTR) 
chloride currents in Madin darby canine kidney cells (MDCK). Therefore, HDAC6 serves 
as a promising target in PKD (Cebotaru et al., 2016). 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease and it has been 
demonstrated that inhibition of HDAC6 leads to reduction of SLE by inhibiting immune 
complex negotiated glomerulonephritis, inflammatory cytokine production and by 
enhancing splenic Tregs (T-regulatory) cells. Furthermore, inhibition of HDAC6 led to 
increase in early pre and pro B cell percentage indicating that manipulation of HDAC6 
leads to decrease in  SLE disease status by altering differentiation of abnormal B and T 
cells (Regna et al., 2016) 
 
 
The role of HDAC6 in relationship with various cancers have been widely studied. It has 
been shown that HDAC6 is upregulated in many type of cancers (Bazzaro et al., 2008; 
Bradbury et al., 2005; Saji et al., 2005; Sakuma et al., 2006; Z. Zhang et al., 2004). Role 
of HDAC6 and its role in formation of aggresome and its relationship to cancer has been 
deeply investigated. Cancer cells gather misfolded protein at a much rapid rate than non-
cancerous cells, for survival of these cancer cells disposal of misfolded proteins via the 
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aggresome or UPS pathway is needed (Rodriguez-Gonzalez et al., 2008). Inhibition of 
UPS with the help of proteasome inhibitors and the aggresome pathway with the help of 
HDAC6 inhibitors might prevent misfolded protein disposal thereby harmful to cancerous 
cells (Teru Hideshima et al., 2005).  It was demonstrated by Lee et al., (2008) that HDAC6 
is upregulated in cells that are transformed by Ras oncogene. They also showed that 
HDAC6-deficient mice and cells are resistant to Ras directed oncogenesis indicating that 
HDAC6 helps in Ras activation and downstream pathways like MAPK and PI3K 
pathways. The authors further went on to show that HDAC6 is needed for cancer cells to 
gain the capacity to resist anoikis thereby assisting in tumor metastasis and invasion 
(Geiger & Peeper, 2007; Y. S. Lee et al., 2008a).   
 
Cortactin is a well-known substrate of HDAC6 (X. Zhang et al., 2007). Upregulation of 
Cortactin has been shown in many cancers and it plays cardinal role in tumor invasiveness 
by aiding cell motility (Weaver, 2008). It aids in cancer cell motility via formation of 
invadopodia and involved in degradation of extracellular matrix (Castro-Castro, Janke, 
Montagnac, Paul-Gilloteaux, & Chavrier, 2012; Rey, Irondelle, Waharte, Lizarraga, & 
Chavrier, 2011; Weaver, 2008).  
 
In several studies, HDAC6 has been demonstrated to be involved in tumor cell invasion 
and formation of cortactin based invadopodia (Arsenault, Brochu-Gaudreau, 
Charbonneau, & Dubois, 2013; Castro-Castro et al., 2012; Rey et al., 2011). It was 
demonstrated by Dhanyamraju et al., (2015) that in SHH driven medulloblastoma, 
endogenous levels of HDAC6 expression was high and HDAC6 is involved in modulation 
of Hh signaling. Pharmacological inhibition of HDAC6 led to reduction in growth of 
tumor in an allograft model and they propose HDAC6 as a unique and potential drug 
target for treatment of Shh driven medulloblastoma (Dhanyamraju et al.,2015).  Recently  
it was shown that expression levels of deacetylases HDAC1 and HDAC2 were elevated 
in SHH driven medulloblastoma (Canettieri et al., 2010; Coni et al., 2017). Specific 
inhibition of these two deacetylases by genetic knock down or by pharmacological means 
leads to positive outcome in mouse models of SHH driven medulloblastoma. They go on 
to show that, mocetinostat (MGCD0103) which is specific inhibitor of HDAC1/2 is also 
a powerful Hh inhibitor and brings about its effect by acetylating Gli1 at lysine 518. 
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Treating SHH-MB mouse models with mocetinostat leads to slow down of tumor growth 
by increasing tumor cell apoptosis and reduction in proliferation thereby prolonging 
survival of mouse. They also propose that inhibition of HDAC1/2 along with HDAC6 
inhibition (Dhanyamraju et al., 2015) in SHH driven MB may bring more synergistic 
effects (Coni et al., 2017b). Apart from these, the role of HDAC6 has also been shown in 
breast  and ovarian cancers (Sri N Batchu et al., 2016) and modulation of HDAC6 can be 
helpful in disease prognosis. HDAC6 also has been demonstrated to play role in platelet 
biology (Sadoul et al., 2012) and inhibition of HDAC6 leads to improvement in cardiac 
function in elderly people (Ferguson & McKinsey, 2015). 
 
Keeping in view, such diverse roles played by HDAC6 in various biological and 
pathobiological processes it is important to modulate its function. Pharmacological 
modulation of HDAC6 is one of the options that can be useful. Though the functions of 
HDAC6 could be modulated by pharmacological means there are limited options and 
further research into HDAC6 modulators with higher specificity and effectivity at lower 
concentrations should be the subject of future studies. Importantly, I was able to establish 
an important role played by HDAC6 in modulating mammalian Hh signaling thereby 
making HDAC6 a unique therapeutic target for treating Hh- directed malignancies. 
 
 
 
Figure I: Dual role of HDAC6 in Hedgehog signaling: (A) When the ligands are absent; basal Hh signaling is  
completely repressed by the help of HDAC6. (B) When the ligands are present; HDAC6 is needed for activation of 
full pathway. 
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8 Appendix 
 
8.1 Supplementary figures 
 
Figure S1: Lack of significant cilia effects due to blockade of HDAC6 (A) Experimental description of two 
approaches performed. The ‘Cilia formation assay’ analyzed inhibition of HDAC6 effects during formation of primary 
cilia. The ‘cilia resorption assay’ investigated whether blockade of HDAC6 resulted in loss (resorption) of pre-
established primary cilia. (B) Primary cilia quantification as determined by detyrosinated tubulin staining in treated 
ShhL2 cells. The mean of three independent experiment is shown with at least 100 counted cells in each experiment. 
Compound conc. as in (B). (C) Representative micrographs of treated ShhL2 cells as shown in (C). Green: 
Detyrosinated tubulin; blue: DAPI, 
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Figure S2: Hdac6 siRNA sequences validation (A) Cell titer assay measuring cytotoxicity of the inhibitors used in 
this study. NIH3T3 cells were grown in full growth medium for 2 days with the indicated compounds. Only TSA (pan-
HDAC inhibitor) led to a significant decrease in viable cells. (B) Targeting hdac6 in MEF[SHH] cells via four single 
siRNAs (contained in the SMARTpool) and its validation. Out of the four siRNAs three result in Hh pathway repression 
as measured by a reduction in Hh target gene expression (Ptch1, Ptch2). I speculate some degree of off-target activity 
with respect to the fourth RNAi sequence which counteracts the expected reduction in Hh target gene expression. 
Alternatively, the efficiency of knock-down might be insufficient for inhibitory effects on Hh target genes. (C) 
Transfection of si Hdac6(pool) in MEF[SHH] cells and its effects on expression levels of other HDAC family members. 
(D) C3H10T1/2 cells transfected with indicated pools of siRNA sequences followed by SAG induction, figure shows 
Alkaline phosphatase staining in blue. (E) Experimental quantification of (D). AP= Alkaline phosphatase. (F) Knock-
down efficiency of Hdac6 mRNA via RNAi in the cells shown in (D) and (E). (G) Wildtype MEFs treated for 48h with 
10 µM ACY-1215 or 4 µM CAY-10603 shows increased tubulin acetylation (Ac-αTub), but has no effect on acetylation 
of nuclear histone H3. 
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Figure S3: Reduction in Hh signaling due to Hdac6-specific inhibition (A) ShhL2 were treated for 48h with the 
indicated compounds in low serum conditions (1% FBS). SANT: 0.2 µM; ACY-1215: 10 µM; CAY-10603: 4 µM; 
Tubacin: 20 µM; TSA: 0.5 µM.  (B)  ShhL2 cells were treated for 48h with the indicated compounds in the 
presence/absence of recombinant human SHH ligand (0.4µg/ml final conc. of SHH C24II), R&D Systems, #1845-SH). 
Fold induction shown by SHH over the corresponding sample without SHH. Concentrations of compound as in (A). 
(C) Expression of Hh target genes in Ptch1-/- MEFs as measured by qPCR. Treatment time was 2days. Concentrations 
of compound as in (A). (D) Expression of Hh target genes in Sufu-/- MEFs transfected with siRNA against Hdac6 or 
Gli2 (positive control) 
 
 
 
 
 
 
- Figure S3 - 
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Figure S4: Inhibition of HDAC6 and its dichotomy on Hh target gene expression (A) Expression of Ptch1 mRNA 
in wildtype MEFs treated with DMSO, ACY-1215 (10 µM) or CAY-10603 (4 µM) for 48 h. Note that Ptch1 expression 
is increased with HDAC6 inhibitors even in the presence of SMO antagonist SANT. However, maximum SAG 
induction is reduced by HDAC6 inhibition. 
 
 
 
 
Figure S5:  Inhibition of HDAC6 in vivo and its effect on Gli1 expression (A) Analysis of Hh target gene expression 
via quantitative real time PCR in allograft tumors taken on 12th day. SOL: Solvent; VIS: Vismodegib; ACY: ACY-
1215. mRNA expression of Ptch1 is reduced but is not statistically significant. 
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Figure S6: Alopecia phenotype in treated mice (A) Alopecia is seen in Vismodegib (VIS) treated allograft mice 
(picture taken on 12th day). Note the hair loss is not seen in solvent (SOL)- or in ACY-1215 (ACY) treated mice. 
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